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 8 
Introduction 
For decades research on the pathogenesis of vascular disease has been focused on classical 
risk factors, including hyperlipidemia, hypertension, smoking, diabetes, sex, age, and familial 
history. However, not all cases can be explained by these well-defined risk factors. Therefore, 
the search for novel potential risk factors is continuing. A central role for inflammation in 
atherogenesis has been established. Current evidence indicates that inflammatory processes 
are implicated in the initiation and the evolution of the atherosclerotic process [22, 31]. The 
initial step in atherosclerosis is probably endothelial dysfunction, which may be caused by a 
risk factor or a combination of several risk factors [31]. Various infectious pathogens, 
including Helicobacter pylori, cytomegalovirus, herpes simplex virus, and Chlamydia (C.) 
pneumoniae, have been considered as potential risk factors for vascular diseases.  
The hypothesis that infection might play a role in the development of vascular diseases 
supposes that infectious agents, such as C. pneumoniae, initiate and progress inflammation, 
which may contribute to the development of vascular disease [11, 18, 31]. After respiratory 
tract infection, C. pneumoniae can reach vascular tissue via infected leukocytes, where it can 
infect cells associated with atherosclerosis (endothelial cells, macrophages and smooth muscle 
cells). Chlamydial lipopolysaccharide and chlamydial heat shock protein 60 kd (cHsp60) may 
contribute to atherogenesis in several ways [18]. Lipopolysaccharide mediates ingestion of 
low-density lipoprotein (LDL) by macrophages infected with C. pneumoniae, leading to the 
formation of foam cells, the characteristic cells of early atherosclerosis. CHsp60 mediates 
oxidation of lipoproteins, which become atherogenic. CHsp60 may also cause 
proinflammatory activation, which promotes atherogenesis [18]. It has been suggested that 
cHsp60 may induce immunological cross-reaction with autoantigens such as human Hsp60 
leading to antibody-mediated endothelial cytotoxicity [26]. Moreover, infected atheroma-
associated cells, such as endothelial cells, seem to produce inflammatory cytokines and 
express leukocyte adhesion molecules. Endothelial infection may stimulate smooth muscle 
cells proliferation, whereas infection of macrophages and smooth muscle cells induces 
production of inflammatory cytokines [18]. It has been suggested that C. pneumoniae may 
cause impaired arterial relaxation and endothelial dysfunction [23]. Moreover, a role for C. 
pneumoniae infection in plaque destabilization has been postulated; it may promote the 
secretion of matrix-degrading metalloproteinases that destabilize the atherosclerotic plaque 
[18].  
Since the reported association between C. pneumoniae and coronary artery disease in 1988, 
the theory of C. pneumoniae as a cause of vascular disease has received considerable attention 
[33]. Many investigations have addressed the possible involvement of C. pneumoniae in 
vascular diseases [19, 21]. Mice and rabbit models of C. pneumoniae infection have been used 
in the evaluation of the association between C. pneumoniae and vascular diseases. Systemic 
dissemination of C. pneumoniae after respiratory infection has been shown in animal model 
studies. Some animal experiments suggested a role for C. pneumoniae in initiation and 
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progression of atherosclerosis-like inflammatory changes, however they did not establish an 
etiologic role of C. pneumoniae in vascular disease [7, 27-29]. Two antibiotic trials in rabbits 
showed that C. pneumoniae increased intimal thickness and induced atherosclerotic changes 
[8, 29]. Early administration of antibiotic therapy reduced these atherogenesis effects of C. 
pneumoniae, however delayed treatment (weeks after infection) was ineffective. It has been 
shown that antibiotic treatment did not affect the presence of C. pneumoniae in rabbits and 
mice [29, 32]. The results of two recent studies in mice and rabbits questioned the effect of 
antibiotic treatment. In a mice model, antibiotic treatment had no effect on atherosclerotic 
changes caused by C. pneumoniae at all [32]. Antibiotic treatment had, in a rabbit model, no 
reducing effect on the prevalence of atherosclerotic lesions but it reduces only the extent of 
the lesions [9]. Furthermore, it has to be mentioned that rabbit and mice models of 
atherosclerosis are not identical to that of human atherosclerosis. Another limitation of 
experimental animal models is that investigations have been limited to rabbit and mice [10]. 
The promising preliminary results of two small human clinical trials, published in 1997, 
increased the enthusiasm for the hypothesis that links C. pneumoniae to vascular diseases [12, 
13]. Gupta et al. [12] randomized 60 patients with myocardial infarction and positive C. 
pneumoniae serology (IgG > 64) to receive either a daily dose of oral azithromycin 500 mg or 
a placebo for 3 or 6 days. Patients in the azithromycin group had lower risk of subsequent 
cardiovascular events after a follow-up period of 18 months. Also, a decrease in IgG titers 
against C. pneumoniae was found in the azithromycin group. Gurfinkel et al. [13] randomized 
202 patients with unstable angina or non-Q-wave myocardial infarction to receive oral 
roxithromycin 150 mg twice daily or placebo for 30 days. A significant reduction in 
subsequent cardiovascular events was found in the roxithromycin group after 1-month follow-
up. However, this reduction was no more significant after 6 months follow-up [14]. 
Furthermore, IgG titers against C. pneumoniae were not influenced by roxithromycin. 
 
Atherosclerosis 
Atherosclerosis evolves in the arterial intima as a result of proliferation of smooth muscle 
cells and accumulation of macrophages, lymphocytes and lipids [31]. As the process 
advances, the atherosclerotic plaque is formed containing smooth muscle cells, collagen, 
elastic fibers, macrophages, lymphocytes, lipids, cellular debris, and calcification. In a more 
advanced stage, the endothelium surface of the lesion is damaged; the plaque becomes 
vascularized leading to hemorrhage and thrombosis formation. Finally, the arterial vessel is 
occluded.  
The pathogenesis of atherosclerosis is not fully understood. Several hypotheses have been 
proposed to explain the etiology of this disease. The widely accepted ‘response to injury’ 
hypothesis postulates that atherogenesis probably starts with endothelial dysfunction as a 
result of exposure to elevated modified LDL, free radicals originated by tobacco abuse, 
diabetes mellitus, elevated homocysteine, genetic mutation and possibly other risk factors not 
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defined yet [31]. Endothelial dysfunction leads to the production of adhesion-molecules that 
increase adherence and invasion of monocytes and T lymphocytes into the arterial intima. 
Subsequently, monocytes/macrophages accumulate LDL and form foam cells. Locally 
produced cytokines and growth factors progress the lesion by stimulating the migration of 
smooth muscle cells from arterial tunica to arterial intima, where they proliferate. The 
involvement of inflammatory responses, including inflammatory cells (macrophages and T 
lymphocytes) and cytokines in all stages of the atherosclerotic process indicates a central role 
for inflammation in atherosclerosis [31]. 
 
Abdominal aortic aneurysm 
Abdominal aortic aneurysm (AAA) is a localized chronic dilatation in the abdominal aorta. It 
results from genetic and acquired weakness in the arterial media. Degradation of extracellular 
matrix proteins is the most important feature in the pathogenesis of AAA, leading to 
fragmentation of elastin and collagen fibers in the aortic wall and subsequently resulting in 
expansion of the arterial wall [24]. There is evidence that genetic factors are implicated in the 
development of AAA. This is supported by the familial clustering of AAA. Also, several 
proteolytic factors are considered as risk factors for AAA. Interaction between these risk 
factors probably promotes proteolytic activity in the arterial wall, which gives rise to 
aneurysmal dilatation [17, 24]. However, the pathogenesis of AAA is not fully understood and 
efforts to identify novel risk factors are continuing. 
 
Venous thrombosis 
Venous thrombosis affects mainly the deep venous system of the legs. Factors that are 
involved in the pathogenesis of venous thrombosis include endothelial injury, stasis and 
hypercoagulation. Adherence of the thrombus to the vascular endothelium characterizes 
venous thrombosis. The thrombus contains coagulated blood, platelets, fibrin and cellular 
components. Acquired and genetic risk factors contribute to the development of venous 
thrombosis [30]. Acquired risk factors include immobilization, trauma, surgery, pregnancy, 
malignancy and female hormones. Genetic factors include coagulation abnormalities such as 
factor V Leiden, protein C deficiency, protein S deficiency, antithrombin deficiency, 
prothrombin 20210A, hyperhomocysteinaemia and high level of factor VIII. However, about 
one-third of episodes of venous thrombosis cannot be explained by the established risk 
factors. 
                                                                                                                                                 Introduction                         
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Chlamydia pneumoniae (Chlamydophila pneumoniae) 
According to the “old” classification of the order Chlamydiales, the family Chlamydiaceae 
contained only the genus Chlamydia, and this genus had four species: C. trachomatis, C. 
psittaci, C. pneumoniae and C. pecorum. Recently a new classification of the order 
Chlamydiales has been presented (figure 1). In the new classification five new species (suis, 
muridarum, abortus, felis and caviae) are added and C. pneumoniae, C. pecorum and C. 
psittaci are moved to the new genus Chlamydophila [6]. The separation of Chlamydia and 
Chlamydophila is based on differences in genome size and protein sequence analysis. In 
addition, in contrast to Chlamydia species, Chlamydophila species do not produce detectable 
glycogen and have one ribosomal operon (Chlamydia species have two). Furthermore, three 
new non Chlamydiaceae families have been added, the Parachlamydiaceae, Waddliaceae and 
Simkaniaceae. A number of eminent chlamidiologists are against the new classification [34]. 
According to these chlamidiologists there is insufficient reason to divide the Chlamydiaceae 
into 2 genera. In this thesis, we did not use the new genus name Chlamydophila, since 
microbiologists and clinicians are used to the “old” genus name Chlamydia. 
 
Order  Family  Genus  species 
       
    Chlamydia  trachomatis 
      suis 
  Chlamydiaceae    muridarum 
       
    Chlamydophila  pneumoniae 
      psittaci 
      abortus 
      felis 
Chlamydiales       caviae 
      pecorum 
       
    Parachlamydia  acanthamoebae 
  Parachlamydiaceae     
    Neochlamydia  hartmanellae 
       
  Waddliaceae  Waddlia  chondrophila 
       
  Simkaniaceae  Simkania  negevensis 
 
Figure 1. The new classification of the order Chlamydiales. 
 
C. pneumoniae is a Gram-negative obligate intracellular bacterium with a biphasic life cycle 
(figure 2). A smaller extracellular infectious form called the elementary body and a larger 
replicating intracellular non-infectious form called the reticulate body characterize the 
development cycle of Chlamydiaceae. After attachment to host cells, elementary bodies enter 
the cell, probably by endocytosis, and differentiate into reticulate bodies. Reticulate bodies 
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replicate, using the host cell energy, and form inclusions. Prior to cell lysis and release from 
the host cell, reticulate bodies transform again into elementary bodies [20]. This biphasic life 
cycle lasts for 48 to 72 hours. 
C. pneumoniae DNA shows little homology with C. trachomatis, C. psittaci and C. 
pecorum, less than 5%, 10% and 10% respectively [20]. Moreover, elementary bodies of C. 
pneumoniae are pear-shaped, whereas those of C. trachomatis, C. psittaci and C. pecorum are 
round-shaped. C. pneumoniae and C. trachomatis have no animal reservoir and humans are 
the only known reservoir, whereas C. psittaci and C. pecorum have an animal reservoir. The 
natural host of C. psittaci is birds and lower mammals, whereas cattle and sheep are the 
natural reservoir of C. pecorum. 
Transmission of C. pneumoniae occurs from person to person probably via respiratory 
secretions. Although survival of C. pneumoniae on surfaces is very short, transmission via this 
way might be also possible. C. pneumoniae infection has an incubation period of  7-21 days. 
This infection is endemic, however, epidemics that last for several months occur every 2-4 
years. Outbreaks have been reported in schools, military bases and nursing homes [2, 5, 35]. 
In contrast to other chlamydial species, the major outer membrane protein (MOMP) of C. 
pneumoniae is not immunodominant and does not contain species-specific antigens [20]. 
Therefore, reactivity to the MOMP is cross-reactive among chlamydial species. The 
immunodominant C. pneumoniae-specific 98-kDa protein seems to be present only in the 
outer membrane complex of C. pneumoniae. Other C. pneumoniae-specific proteins include 
the 43-kDa protein and proteins with molecular mass between 50 and 60 kDa [20]. 
 
   
                
                       EB attachment to host cell and uptake 
           
           
            
 
 
 
          host cell lysis and release of EBs                       differentiation   of EB into RB  
 
             
 
    
          
          transformation of RBs into EBs                                                 replication of RB   
 
Figure 2. The development cycle of C. pneumoniae. EB, elementary body; RB, reticulate body. 
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Infection with C. pneumoniae induces serum immunoglobulin responses including IgM, 
IgA, and IgG. In primary infection, IgM response appears within 3 weeks and IgG response 
after 6 to 8 weeks. In re-infection, IgM response may be absent and the IgG response occurs 
within 1 to 2 weeks [16]. The biological half-life of serum IgA is about 7 days, whereas the 
half-life of IgG is 23 days [16]. Therefore, it has been suggested that the persistence of 
positive IgA titer can be used as a marker for chronic infection. However, the Centers of 
Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control 
(Canada) recommend not to use neither elevated IgA nor any other serologic markers as 
criteria for chronic or persistent infection [4]. It has been suggested that high levels of IgG 
interfere with determination of IgA titers [3]. In a serological study IgA was detectable in only 
17 to 42% of patients with serological evidence (IgG and /or IgM) for acute or recent 
infection [36].  
The seroprevalence of C. pneumoniae, determined by the MIF test, increases from 10% at 
the age of 5-10 years to 50% of adults (> 20 years) reaching 70-80% among persons above the 
age of 50 years [15]. Re-infection throughout life with C. pneumoniae is probably very 
common. Seroprevalence is higher in adult males than in adult females; so far, no explanation 
for this has been found. However, there is no difference in seroprevalence between sexes 
under 15 years of age. 
C. pneumoniae, Mycoplasma pneumoniae and Legionella pneumophila cause community-
acquired pneumonia. However, the data on the significance of these bacteria as agents of 
community-acquired pneumonia are inconsistent. According to different studies, these 
pathogens are responsible for 2-30% of community-acquired pneumonia [15]. It has been 
demonstrated that these rates are influenced by the diagnostic serologic criteria used [25]. C. 
pneumoniae is also associated with acute bronchitis and pharingitis. As with community-
acquired pneumonia, conflicting data have been reported on the rate of C. pneumoniae as the 
agent of acute bronchitis (range 2% - 25%) [1]. These data depend on the diagnostic methods 
and criteria used. 
 
Outline of the thesis 
The aim of this thesis is to assess the possible association between C. pneumoniae and 
vascular diseases. 
In chapter 2, four different methods for DNA extraction from vascular tissue are compared. 
A homogenous solution was prepared from aorta tissue samples inoculated with known 
concentrations of C. pneumoniae DNA. The spiked dilution series were tested by four 
procedures to extract C. pneumoniae DNA. Extracted DNA was detected by polymerase chain 
reaction (PCR).  
In a case-control study (chapter 3), the association between abdominal aortic aneurysm 
(AAA) and C. pneumoniae is investigated. Using PCR, we explored the presence of C. 
pneumoniae DNA in peripheral blood cells samples of patients with AAA and control 
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subjects. Also, the seroepidemiologic association between AAA and C. pneumoniae was 
investigated.  
In chapter 4, the impact of serologic methodology on the association between C. 
pneumoniae and AAA is assessed. The association between C. pneumoniae and AAA was 
investigated by five serologic tests. In addition, the agreement between these tests was 
evaluated. 
We studied, in chapter 5, the involvement of C. pneumoniae in the inflammation associated 
with venous thrombosis. Using PCR and serology, the association between C. pneumoniae 
and venous thrombosis was assessed in a case-control study.  
In chapter 6, the association between C. pneumoniae and atherosclerosis is assessed. Also, 
the correlation between the detection of C. pneumoniae by PCR and immunohistochemical 
staining (IHC) in vascular specimens was evaluated. The correlation between C. pneumoniae 
serology and the detection of this pathogen was analyzed.  
Chapter 7 deals with the hypothesis that not only C. pneumoniae but also Mycoplasma 
pneumoniae is a plausible candidate to play a role in the pathogenesis of atherosclerosis, 
because of its ability to induce chronic inflammation and its epidemiological behavior that 
simulates the epidemiological behavior of C. pneumoniae. We investigated, by PCR, the 
presence of M. pneumoniae in atheromas and in degenerative heart valve specimens obtained 
from patients undergoing vascular surgery.  
Chapter 8 addresses the impact of molecular methodological factors on the association 
between C. pneumoniae and vascular disease. Vascular specimens were tested by three PCR 
assays: a 16S PCR-based reverse line blot assay, a single-step PCR and a nested PCR. We, 
also, explored the impact of hybridization and the use of different DNA polymerase enzymes 
on the results of the PCR assays.  
In chapter 9, a randomized, double-blind, placebo-controlled trial is described. In this trial, 
we investigated the effect of clarithromycin on the presence of C. pneumoniae in vascular 
tissue of patients with coronary artery disease. Also, the effect of clarithromycin on 
Chlamydia IgG titers was evaluated. IHC, a real-time PCR and an industry-developed 
research-use-only PCR assay were used to assess the eradication of C. pneumoniae from 
vascular specimens obtained from the study population during coronary artery bypass graft 
surgery.  
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Abstract 
The objective of this study was to compare four procedures for Chlamydia pneumoniae DNA 
extraction from vascular tissue. The NucliSens Kit, the QIAamp tissue DNA MiniKit, buffer-
saturated phenol and the Geneclean II Kit were evaluated, based on the yield of recovered 
DNA, using PCR to detect C. pneumoniae in vascular tissue. The QIAamp tissue procedure 
had the highest detection level (0.004 inclusion-forming units/sample). All methods, except 
NucliSens (70 min), had a short handling time (30–40 min). Costs varied from 0.5 to 3.2 euro. 
 
Introduction  
Chlamydia pneumoniae has been associated with atherosclerosis, initially on the basis of 
seroepidemiologic studies [1, 2]. Two recent studies, however, have failed to demonstrate any 
such connection [3, 4]. Subsequently, further evidence has been provided by the detection of 
C. pneumoniae in atherosclerotic tissue by polymerase chain reaction (PCR), 
immunocytochemistry [5–7], and isolation in culture. Whether C. pneumoniae plays a role in 
the pathogenesis of atherosclerosis is still not known. Although serologic assays are 
considered the reference diagnostic method for C. pneumoniae infections, PCR is potentially 
an important tool for further studies in this field. C. pneumoniae PCR is, however, not yet 
standardized. Several PCR assays have been used to detect C. pneumoniae in vascular tissues. 
However, a considerable variation in the detection rate of C. pneumoniae, ranging from 0% to 
100%, has been reported by different investigators [5–10]. This phenomenon can be explained 
by the differences between the populations studied, by sampling error, and by differences in 
the PCR techniques applied. The potential for differences in performance between PCR 
techniques is well known. For example, the sensitivity of PCR for the detection of 
Mycobacterium tuberculosis in samples containing low numbers of microorganisms varied 
among seven laboratories from 2% to 90% [11]. A multicenter study showed major inter-
laboratory differences in the detection rate of C. pneumoniae in endarterectomy specimens 
[12]. Therefore, it is important to determine a more standardized procedure that includes DNA 
extraction from specimens. In order to detect C. pneumoniae by PCR, efficient release of C. 
pneumoniae DNA from vascular tissue and adequate removal of PCR inhibitors (lipids and 
calcification) are essential [13]. The purpose of this study is to compare four procedures for C. 
pneumoniae DNA extraction from vascular tissue. 
 
Materials and Methods  
Vascular samples were obtained from 30 patients during cardiac surgery (coronary artery 
bypass graft—CABG). During this procedure, a punch biopsy through the aortic wall is 
routinely taken. This biopsy material was stored at 4 oC in 200 µL of lysis buffer (1M Tris, pH 
7.0, 0.5 mM EDTA, 5 M NaCl, 1% sodium docecyl sulfate (SDS), 20mg/mL proteinase K) 
for a maximum of 24 h. Subsequently, the sample was lyzed by adding 20 µL of proteinase K 
(20 mg/mL, Qiagen, Hilden, Germany) and incubating overnight at 56 oC. After cell lysis, a 
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homogeneous solution was made by pooling all 30 lysates. Seven 900-µL portions of the 
homogenate were inoculated with decreasing concentrations of inclusion-forming units (IFUs) 
of C. pneumoniae strain TW 183. Portion number 8, containing AE buffer (QIAamp, Qiagen), 
was used as a negative control.   
Two hundred and five microliters of each portion (corresponding to the concentrations of 
the dilution series (10- and 5-fold): 10 000, 1000, 100, 10, and 2, 0.4, 0.08 IFU per 205 µL; 
per PCR (this is 500, 50, 5, 0.5, 0.1, 0.02 and 0.004 IFU) was subjected to each of four 
methods of DNA extraction.  
In the first procedure NucliSens (Organon Teknika, Boxtel, The Netherlands) used, based on 
the method of Boom et al. [14], according to the manufacturer’s instructions. This technique is 
based on the mechanism whereby DNA binds to glass particles (silica) in a high concentration 
of chaotropic salt, while contaminants such as proteins, carbohydrates and ions do not. A 
wash procedure is repeated three times to remove all contaminants (with wash buffer, or 70% 
ethanol or acetone). DNA is eluted from the silica by resuspension of the silica complexes in 
NucliSens elution buffer. 
In the second procedure the QIAamp DNA MiniKit (Qiagen) was used, according to the 
QIAamp tissue protocol in the manufacturer’s instructions. This method uses a QIAamp spin 
column to which DNA binds in the presence of buffer AL and ethanol. Two wash steps, in 
which AW1 buffer and AW2 buffer succeed each other, are performed to remove 
contaminants. AE buffer is finally used for elution of the DNA from the spin column.  
In the third procedure buffer-saturated phenol (Life Technologies, Breda, the Netherlands) 
was used. This method is home-made, based on ‘classical’ phenol extraction. In this method, 
200 µL of buffer-saturated phenol (pH 7.5–7.8) was added to 205 µL of sample in a 1.5-mL 
screw-cap plastic tube, vortexed for 1 min, and centrifuged for 5 min at 20 000 g. The 
aqueous supernatant was transferred to another tube, which also contained 200 µL of buffer-
saturated phenol. After homogenizing and centrifuging (5 min at 20 000 g), the aqueous 
supernatant was transferred to a 1.5-mL screw-cap plastic tube containing 20 µL of 3M 
sodium acetate (pH 5.2) and vortexed. Ice-cold absolute ethanol (440 µL) was added, and the 
mixture was homogenized and incubated at -20 oC for 15 min. The sample was centrifuged 
(15 min, 20 000 g) to pellet the DNA products. The supernatant was removed, and the pellet 
resuspended in 250 µL of 70% ethanol, vortexed and centrifuged for 5 min (20000 g). The 
supernatant was removed again, and a quick centrifuge spin was done, so that the remaining 
ethanol could be removed. The pellet was air-dried in a half-open tube and suspended in 100 
µL of AE buffer by vortexing. 
In the fourth procedure the Geneclean II Kit (Qbiogene, Illkirch, France) was used, 
according to the manufacturer’s instructions. Like the first method, this method is also based 
on the fact that DNA binds to glass particles in a high concentration of chaotropic salt. Here, 
the DNA binds to Glassmilk. The Glassmilk–DNA pellet is washed once with New Wash.  
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All DNA elutions (in 100 µL of AE buffer, (Qiagen)) were resuspended at 80 oC for 5 min, 
which completed the DNA extraction. 
An identical PCR assay was performed on 5 µL of each sample to detect C. pneumoniae 
DNA, irrespective of extraction method. All amplification steps, assay conditions, signals, 
visualization steps and hybridization procedures were identical. 
 
Polymerase chain reaction 
Primers CpnA (5’-TGA CAA CTG TAG AAA TAC AGC-3’) and CpnB (5’-CGC CTC TCT 
CCT ATA AAT-3’) were used in a PCR based on the 16S rRNA gene sequence as described 
by Gaydos et al. [15]. 
The PCR reaction mixture contained 30 pmol of each primer, 3mM MgCl2, 200 µM dNTPs 
(dTTP is replaced by dUTP), 2.5 units of AmpliTaq Gold DNA polymerase (Perkin Elmer 
Cetus, Norwalk, Conn., USA), 10 x PCR buffer II (Perkin Elmer), and 1.25 µL of internal 
control.  
An internal control was added in each reaction to enable detection of inhibition of the PCR 
reaction and prevent false-negative PCR results. The internal control template DNA consisted 
of a PCR product of an unknown fragment of Escherichia coli DNA that yields a 150-bp PCR 
product in combination with primer PINTK (5’-(ACTG x 4)-AC-3’).  
The PCR amplification was performed as follows: after addition of 5 µL of template DNA 
in a final volume of 25 µL of PCR reaction mixture, samples were subjected to the following 
PCR program: 10 min at 96 oC, followed by 40 cycles of 30 s at 95 oC, 30 s at 55 oC, and 1 
min at 72 oC. A final step of 10 min at 72 oC completed the PCR in a thermocycler (9600, 
Perkin Elmer). A negative PCR mix control and a negative sample-processing control were 
included in each PCR run with every five samples to detect false-positive results.  
For final product detection, amplification products were examined by agarose gel 
electrophoresis and dot-blot hybridization as follows. Eight microliters of each PCR product 
was analyzed by agarose gel electrophoresis on 2% agarose gels in TBE buffer containing 
ethidium bromide. PCR products were visualized under UV transillumination and 
photographed. If the 450-bp Chlamydia-derived band was visible (with or without the 150-bp 
band), the sample was considered positive. If only the 150-bp band of the internal control was 
visible, the sample was considered negative. If no bands were visible, the PCR was considered 
inhibited, and the sample was repurified and retested by PCR.  
 
Dot-blot hybridization 
Hybridization of 5 µL of the PCR products was performed using a 5’-biotinylated C. 
pneumoniae-specific probe, Cpneu-B: 5’-ACACACGTGCTACAATGGTT-3’. Hybridization 
signals were visualized using streptavidin peroxidase (Boehringer Mannheim, Mannheim, 
Germany) and ECL detection reagents (Amersham, Biosciences UK limited, Little Chatfont, 
UK). 
                                                                                                                            DNA extraction methods 
 23
To minimize the risk of contamination, sample preparation, PCR amplification and analysis 
of the PCR product were performed in separate rooms. 
 
Analysis  
Comparison of the four procedures was done using gel electrophoresis and dot-blot 
hybridization. Each procedure was also compared for overall time consumption and hands-on 
time per sample. Hands-on time was defined as time needed by the technician working with 
this procedure, and overall time as the total time, including centrifuging, incubation, etc. 
Finally, the average costs per sample were estimated in euros, calculated from the price of the 
commercial kit and material (e.g. ethanol), excluding the use of materials such as plastic 
tubes, divided by the number of samples. 
 
 
 
 
 
Figure1. Agarose gel electrophoresis of PCR products 
(Chlamydia pneumoniae) using four DNA extraction 
methods. 
* Internal control bands.
             NucliSens                               QIAamp                     
 
*? 
 
 
 
 
 
 
*? 
             Phenol                                    Geneclean II        
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Results 
Figure 1 shows the results of C. pneumoniae detection for each method. The detection levels 
ranged from 0.004 IFU per sample for QIAamp, to 0.1 IFU per sample for phenol extraction 
and NucliSens, and 0.5 IFU per sample for Geneclean II (table 1). 
The least labor-intensive method was the Geneclean II, with a hands-on time of 30 min, and 
an overall time of 60 min (table 1). Costs per sample of various methods show that buffer-
saturated phenol was the cheapest method, with an average of 0.5 euro per sample (table 1). 
 
Table 1. DNA extraction methods for Chlamydia pneumoniae in vascular tissue 
  Time consumption (min)  
Method Detection level 
IFU/sample 
Hands-on time Total time Costs (euro) 
per sample 
NucliSens 0.1 70 115 3.2 
QIAamp  0.004 35  60 2.9 
Phenol 0.1 40 105 0.5 
Geneclean II 0.5 30  60 1.4 
 
 
Discussion 
In this study, we compared four different DNA extraction methods. To create realistic study 
material, a homogenate solution was prepared from aorta tissue samples inoculated with IFUs 
from C. pneumoniae. The QIAamp DNA MiniKit extraction method detected the lowest 
amount of IFUs by far. Also, it is a rapid and easy-to-perform procedure. The associated costs 
represent a disadvantage. 
Several factors influence the ability of PCR to detect C. pneumoniae, including sample 
preparation, DNA extraction, amplification assays, and visualization procedures. 
Standardization of these factors was therefore approached in the present study. 
Because C. pneumoniae is an intracellular pathogen, vascular tissue was treated with 
proteinase K to produce tissue cell lysis and release C. pneumoniae DNA, if present. The 
aorta samples used in the present study were macroscopically non-atherosclerotic, and the 
expected positivity rate was low [16]. Since the amount of C. pneumoniae in the study 
materials was unknown, a homogeneous pool of all 30 lysates was made and inoculated with 
decreasing concentrations of IFUs to enable us to compare DNA extraction methods. It should 
be mentioned that the concentration of C. pneumoniae in the dilution series was very similar, 
though it is impossible to achieve identical concentrations. Moreover, it is not known whether 
the ability of the four procedures to extract C. pneumoniae DNA from spiked materials is the 
same as their ability to extract DNA from patient materials [12].  
A multicenter study [12] demonstrated that the sensitivity of a PCR assay does not 
necessarily correspond with the ability to detect C. pneumoniae in patient material, without a 
logical explanation. In the present study, we performed one PCR assay, and because there is 
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no reference assay available, one should view the results of the present study in the light of 
the absence of a reference PCR assay. 
Taking the limitations of the present study into consideration, we can conclude that QIAamp 
is a useful and sensitive DNA extraction method, but further effort to optimize and 
standardize DNA extraction methods is needed.  
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Abstract 
Recent studies have suggested that Chlamydia pneumoniae infection is a risk factor for 
abdominal aortic aneurysm. This study explores the presence of C. pneumoniae DNA in 
buffy-coat samples of control subjects and of patients with abdominal aortic aneurysm. The 
seroepidemiological association between abdominal aortic aneurysm and C. pneumoniae was 
also investigated. Buffy-coat samples and serum specimens were obtained from 88 patients 
and 88 control subjects. Detection of C. pneumoniae DNA in buffy-coat samples and 
measurement of IgG antibodies to C. pneumoniae in serum specimens were performed by 
polymerase chain reaction and microimmunofluorescence, respectively. C. pneumoniae DNA 
was detected in buffy-coat samples of 18 (20%) patients and 8 (9%) control subjects (adjusted 
odds ratio 2.9, 95% confidence interval 1-8.5). IgG antibodies to C. pneumoniae were 
detected in 85 (97%) patients and 71 (81%) control subjects (adjusted odds ratio 7.2, 95% 
confidence interval 1.7-31). The results show an association abdominal aortic aneurysm and 
either the presence of C. pneumoniae DNA in buffy-coat samples or IgG antibodies to C. 
pneumoniae. These findings support the hypothesis that previous infection with C. 
pneumoniae might be a risk factor for abdominal aortic aneurysm. 
 
Introduction  
Several risk factors have been identified as playing a role in the pathogenesis of 
atherosclerosis, the most important process in cardiovascular diseases. In addition to classic 
risk factors such as hypercholesterolemia, hypertension and cigarette smoking, other potential 
risk factors including infectious diseases, have recently gained attention [1]. Atherosclerosis 
has been considered as the most important risk factor for the development of abdominal aortic 
aneurysm (AAA). Later studies demonstrated the importance of other factors, including 
genetic factors, familial clustering and several proteolytic factors that interfere with matrix 
components of the aortic wall [2]. 
C. pneumoniae is a common cause of respiratory tract infections and has been linked with 
atherosclerosis and AAA [1, 3]. Association between seropositivity for C. pneumoniae and 
coronary artery disease or myocardial infarction is reported [1, 4]. However, two recent 
studies failed to demonstrate such a seroepidemiological relationship [5, 6]. C. pneumoniae 
has been detected by polymerase chain reaction (PCR) assays and immunohistochemistry in 
arterial atherosclerotic lesions and AAA tissue [3, 7, 8]. To evaluate the clinical effect of 
antibiotic therapy in patients with coronary artery disease, clinical antibiotic trials have been 
reported, and several large clinical trials are underway [9]. The preliminary clinical trials 
concluded that antibiotics lead to reduction in cardiovascular events and in markers of 
inflammation [10-12].  
To identify persons with infected vascular tissues, diseased tissues obtained during surgery 
have been investigated. It has been suggested that detection of circulating C. pneumoniae 
DNA is a useful and an appropriate assay that can predict vascular infection [13-15]. One 
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study has reported the detection of C. pneumoniae in peripheral blood mononuclear cells 
(PBMCs) from patients with AAA [13]. However, no case-control studies have been 
conducted to explore the association between the detection of C. pneumoniae DNA in 
peripheral blood cells and AAA.  
We investigated, using PCR, the association between AAA and the presence of C. 
pneumoniae DNA in buffy-coat samples. Serological association was investigated using a 
microimmunofluorescence (MIF) test. 
 
Materials and Methods  
Study Population 
The study population included 88 patients with AAA and 88 control subjects. From August 
1996 to September 1997, a case-control study was performed to evaluate the role of 
hyperhomocysteinemia in AAA (unpublished data). Subsequently, the association between C. 
pneumoniae and AAA was investigated in the study population. During the study period, all 
patients who presented with AAA (ultrasonographically proven infrarenal aortic diameter > 
30 mm) or who underwent surgery for AAA at our hospital were invited to participate in this 
study. The patients included were asked to bring a friend or a neighbor as a control subject. 
Patients and control subjects were matched for sex and age (± 5 years). Some patients brought 
a control subject who was not of the same sex and age. These control subjects were matched 
to other patients. For 38 patients we failed to recruit a control subject using this method. 
These patients were matched to friends or family members of hospital staff personnel (n = 31) 
or to patients who visited the internal medicine outpatient clinic for reasons not related to 
vascular disease (n = 6). Ultrasonography was performed in all control subjects to exclude 
AAA; if an abdominal aortic diameter of > 30 mm was found, the control subject was not 
included.  
Hypertension was defined as the use of antihypertensive medication or blood pressure 
>140/90 mmHg. Hypercholesterolemia was defined as the use of cholesterol-lowering 
medication or serum cholesterol >8 mmol/l. Diabetes mellitus was defined as the use of 
medication for diabetes mellitus or fasting serum glucose > 7.8 mmol/l. 
Buffy-coat samples and serum specimens were obtained from patients and control subjects. 
The study was approved by the local ethical committee, and all subjects gave informed 
consent.  
 
Sample Preparation and Polymerase Chain Reaction 
Separation of buffy-coats from blood samples and DNA extraction were performed on the 
same day the samples were received. Buffy-coat samples were prepared by centrifuging 
EDTA-whole blood 3300 xg for 10 min. PCR samples were prepared by extracting total DNA 
from 200 µl of the buffy-coat fraction using the QIAamp DNA minikit (Qiagen, Germany). 
Processed specimens were stored at 4 °C for 12 months before the PCR assay was done. As 
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template in PCR, 5 µl of  a 200 µl elution sample was used. Buffy-coat samples of 88 patients 
and 88 control subjects were examined by PCR for the presence of C. pneumoniae DNA using 
a validated PCR assay as described by Gaydos et al. [16]. The primers CpnA (5’-TGA CAA 
CTG TAG AAA TAC AGC-3’) and CpnB (5’-CGC CTC TCT CCT ATA AAT-3’) were used 
in a PCR assay based on the sequence of the 16S rRNA gene. The sensitivity of the PCR 
assay was experimentally determined by spiking known concentrations of C. pneumoniae 
DNA in a pool of negative clinical material; the lowest detection limit was 0.1 inclusion-
forming unit, indicating good sensitivity. A negative control, containing all PCR reagents 
without specimens, was processed with every five samples. To control for inhibition of the 
PCR reaction, a second sample of each buffy-coat sample was spiked with C. pneumoniae 
target DNA. If the spiked sample was negative, the sample was considered inhibited. 
Inhibited PCR samples were repurified and retested using 2.5 µl of the samples. To minimize 
the risk of contamination, sample processing and the PCR assay were performed in separate 
rooms, and to prevent carryover of previous PCRs, uracil DNA glycosylase (UDG) and 
deoxyuridine triphosphate (dUTP) were used.  
PCR products were examined visually after electrophoresis in 2% ethidium bromide- 
stained agarose gels. To confirm positive results, 3 µl of the PCR product was spotted and 
hybridized with a 21 bp 5’-biotinylated probe CPNEU-B (5’-GAC ACA CGT ACA ATG 
GTT-3’). Hybridization signals were examined visually using streptavidin-peroxidase and 
enhanced chemiluminescence detection reagents (Amersham, UK). 
 
Serological investigations 
Ten microlitres of the serum fraction was used for serological investigations. Serum 
specimens were tested for the presence of IgG antibodies against C. pneumoniae (TW 183). 
The serological testing was performed by a MIF test (MRL Diagnostics, USA) as described 
previously [17, 18]. An IgG antibody titer > 1:16 was considered positive. All serological 
tests were performed blindly by the same technician. 
 
Statistical Analysis 
Matched odds ratios were calculated as an estimate of the relative risk for AAA in subjects 
with positive C. pneumoniae PCR and positive serological results. Using SPSS software 
(SPSS, USA), confidence intervals and adjusted odds ratios were calculated and a 
multivariate analysis was performed in order to adjust for other cardiovascular, 
cerebrovascular and peripheral vascular diseases and for classic risk factors of atherosclerosis. 
Association between circulating C. pneumoniae DNA and IgG antibodies was analyzed by 
the chi-square test. The t test for two independent samples with equal variance was used to 
analyze the association between pack-years of cigarette smoking (A pack-year was defined as 
smoking 20 cigarettes/day for 1 year) and circulating C. pneumoniae DNA and IgG 
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antibodies, and to compare the geometric means titers (GMTs) of patients with those of 
control subjects. 
 
Results 
During the study period, 149 consecutive patients with AAA were invited to participate in the 
study, but only 89 took part. Eight control subjects were excluded because of asymptomatic 
AAA. For one patient, aged 94 years, we failed to find a control subject. Thus, the study 
population consisted of 88 cases and 88 controls. Further characteristics of the study 
population are shown in table 1. 
 
Table 1. Baseline characteristics of patients with abdominal aortic aneurysm and controls 
Characteristic Patients 
(n = 88) 
Control subjects 
(n = 88) 
P value 
Age in yearsa (range)  69 (45-85) 67 (44-83) NS c 
Male/femalea 81/7 81/7 NS 
Aneurysm    
  Under control 35   
  Operated 53   
  Elective                       40   
  Symptomatic   7   
  Ruptured   6   
  Family history of aneurysm 16   9 NS 
History    
  Myocardial infarction 26   9 <0.01 
  Cerebrovascular disease   9   4 NS 
  Pulmonary embolism   2   3 NS 
  Chronic obstructive pulmonary disease 24 13 NS 
  Peripheral vascular disease 19   4 <0.01 
  Diabetes mellitus   6   4 NS 
Smoking    
  Pack-years of cigarette smokingb (±SD) 34 (±33) 23 (±22) <0.01 
Medication    
  Antihypertensive drugs   48   28 <0.01 
  Cholesterol-lowering drugs   28    8 <0.001 
  Nonsteroidal anti-inflammatory drugs   37  17 <0.01 
Mean systolic blood pressure, mmHg (SEM) 159 (2.4) 158 (2.6) NS 
Mean diastolic blood pressure, mmHg (SEM)   85 (1.2)   87 (1.2) NS 
Mean cholesterol, mmol/l (SEM)   5.7 (1.13)    5.7 (0.10) NS 
a Patients and controls were matched for age and sex; b A pack-year was defined as smoking 20 
cigarettes/day for 1 year; c NS, not significant. 
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Buffy-coat samples from patients and controls were tested for the presence of C. 
pneumoniae DNA. Samples from three patients and two controls showed PCR inhibition. 
When these five samples were retested using 2.5 µl of the samples, no PCR inhibition was 
found. PCR detected C. pneumoniae DNA in buffy-coat samples of 18 (20%) patients and 8 
(9%) control subjects (p = 0.03). The matched odds ratio of association between AAA and the 
presence of C. pneumoniae DNA in buffy-coat samples was 2.6 (95%CI, 1.1-6.3). 
Utilizing the MIF test, specific IgG antibodies to C. pneumoniae were detected in 85 (97%) 
patients and 71 (81%) control subjects. The matched odds ratio of association between AAA 
and seropositivity for C. pneumoniae was 6.8 (95% CI, 2-24). The association was stronger in 
the lower IgG titers than in the higher IgG titers (table 2). The GMT of IgG antibodies to C. 
pneumoniae was significantly higher in patients than in control subjects 1:191 and 1:97, 
respectively. A multivariate analysis was performed to adjust for classic risk factors of 
atherosclerosis, including hypertension, hypercholesterolemia, diabetes mellitus and pack-
years of cigarette smoking. History of cerebrovascular disease, peripheral vascular disease 
and myocardial infarction was also included in this analysis. Odds ratios did not decrease after 
correction for these factors. Adjusted odds ratios were 2.9 (95% CI, 1-8.5) for circulating C. 
pneumoniae DNA, and 7.2 (95% CI, 1.7-31) for IgG antibodies to C. pneumoniae. 
 
Table 2. Pairwise distribution of PCR results and IgG antibodies to C. pneumoniae in patients and 
control subjects 
 Patient & control 
both positive  
Patient only  
positive 
Control only 
positive  
Patient & control 
both negative 
Matched odds 
ratio (95% CI) 
PCR  2 16  6 64 2.6 (1.1-6.3) 
IgG      
  >1:16 69        16  2  1          6.8 (2.0-24) 
  >1:32 64 18  5  1 3.6 (1.2-12.4) 
  >1:64 56 23  5  4 4.6 (1.7-15.5) 
  >1:128 38 29 10 11 2.9 (1.4-6.7) 
  >1:256 21  31 11 25 2.3 (1.4-6.2) 
  >1:512  6 17 16 49 1.1 (0.5-2.3) 
 
 
In one control subject in whom the IgG antibody titer was negative, C. pneumoniae DNA 
was detected in the buffy-coat sample by PCR. Detection of C. pneumoniae was not 
associated with a higher GMT. The GMT of IgG antibodies in the 26 cases with positive PCR 
was similar to the GMT in the 150 cases with negative PCR (1:128).  
Table 3 shows the association between detection of circulating C. pneumoniae DNA and the 
prevalence of circulating IgG antibodies to C. pneumoniae in the study subjects and in four 
previous studies. 
No evidence of association was found between smoking and either IgG antibody titers or the 
detection of C. pneumoniae DNA in buffy-coat samples. The pack-years of cigarette smoking 
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were 20 (±17) in subjects who were PCR positive versus 30 (±29) in subjects who were PCR 
negative (P = 0.1). The pack-years of cigarette smoking were 30 (±29) and 18 (±14) in 
subjects with positive IgG titers and negative IgG titers, respectively (p = NS).  
No association was found between age and detection of circulating C. pneumoniae DNA. 
The mean age of PCR-positive and PCR-negative subjects was 67 (±10) years and 67 (±7) 
years, respectively (P = NS). Results of serological investigations were similar: the mean age 
of IgG-positive and IgG-negative subjects was 66 years (±10) and 67 years (±7), respectively 
(P = NS). 
A multivariate analysis to control for classic risk factors of atherosclerosis showed that neither PCR-
positive nor IgG-positive results in control subjects were associated with those risk factors. 
 
Discussion  
This study shows an association between AAA and C. pneumoniae, which was demonstrated 
by a significantly higher detection rate of C. pneumoniae DNA in buffy-coat samples of 
patients with AAA than in samples of control subjects. The serological results emphasize the 
association between AAA and C. pneumoniae. Patients had IgG antibodies to C. pneumoniae 
more frequently and at higher titers than control subjects. The odds ratios did not decrease 
after adjustment for other risk factors of abdominal aneurysms, which implies that chlamydial 
infection is an independent risk factor for AAA. To minimize bias and confounding factors, 
we matched patients and control subjects for sex and age. In addition, to prevent differences 
in socioeconomic status, friends and neighbors of patients were included as control subjects, 
when possible. 
The seroprevalence of C. pneumoniae was high, even in the control group. These results are 
consistent with the seropositivity rates reported previously among healthy population [19-21]. 
Eight pathological studies investigated the presence of C. pneumoniae in AAA, but only 
three included control tissue samples (table 4). Two studies failed to detect C. pneumoniae 
DNA in AAA [22, 23], and in one study PCR was not performed [24]. The remaining five 
studies reported rates of positive PCR results ranging from 35 to 100% [3, 13, 25-27]. 
It has been suggested that detection of circulating C. pneumoniae DNA might be an 
appropriate method to identify patients with chronic C. pneumoniae infection [13, 14]. There 
is, however, variation between published reports in the detection rates of C. pneumoniae DNA 
(tables 3, 4). These differences might be partly explained by population differences and 
methodological differences, including the DNA extraction method and the PCR assay [28]. 
Another important difference is the type of material tested. In three studies peripheral blood 
mononuclear cells were tested [13, 14, 29], in one study sera samples [30], and in the present 
study buffy-coat samples. As stated by Boman and Gaydos [28], it remains to be determined 
which sample type (buffy-coat, peripheral blood mononuclear cells or monocytes) is the most 
appropriate and provides the best results. The advantage of detection of C. pneumoniae DNA 
in buffy-coat samples is that the procedure of cell separation is easy and not time-consuming.  
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Table 3. Association between circulating C. pneumoniae DNA (PCR+) and IgG antibodies to C. 
pneumoniae (MIF+) in the present study and in four previous studies 
Reference Material No. of 
specimens
PCR+,  
MIF+
PCR-, 
MIF-
PCR+, 
MIF-
PCR-, 
MIF+ 
P value 
[13] PBMC     41 19  15   0     7 <0.001 
[14] PBMC 1180 76 323 23 758 0.2 
[29] PBMC   153 81     8   3   61 0.07 
[30] serum   247 35 116 20   76 0.002 
Present study Buffy-coats   176 25   19   1 131 0.3 
MIF, microimmunofluorescence; PBMC, peripheral blood mononuclear cells. 
 
Blasi et al. [13] have shown that there is a correlation between the presence C. pneumoniae 
DNA in peripheral blood mononuclear cells and its presence in the aneurysm wall. They 
investigated AAA tissue and peripheral blood mononuclear cells of 41 patients with AAA, 
and in 39% of the patients C. pneumoniae DNA was detected in both peripheral blood 
mononuclear cells and AAA tissue. However, no materials from control subjects were 
included in that study. The present study is the first case-control study that investigates the 
association between AAA and the detection of C. pneumoniae DNA in buffy-coat samples. 
Our results support the hypothesis that C. pneumoniae is associated with AAA. 
Controversial results have been reported about the association between the circulating C. 
pneumoniae DNA and antibody titers to C. pneumoniae (table 3). Two previous studies have 
demonstrated an association between circulating C. pneumoniae DNA and circulating IgG 
antibodies to C. pneumoniae [13, 30]. Two other studies failed to demonstrate such an 
association [14, 29]. Moreover, in the present study no association was found between the 
presence of C. pneumoniae DNA in the buffy-coat samples and the prevalence of IgG 
antibodies.  
Association between smoking and antibody titers to C. pneumoniae has been reported, and 
smoking was suggested to be a confounder of the association between seropositivity and 
atherosclerosis [31]. This finding was not confirmed by a recent study [32]. We found no 
association between cigarette smoking and either seropositivity or the presence of C. 
pneumoniae DNA in buffy-coat samples of patients with AAA. This suggests that smoking 
has no confounding effect on the association between C. pneumoniae and AAA. 
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Table 4. Studies on the presence of C. pneumoniae in abdominal aortic aneurysm specimens and 
control specimens 
Reference  Number of specimens 
AAA             controls 
No. (%) of specimens positive for C. pneumoniae  
                   PCR                 IHC 
   AAA                   Controls AAA                      Controls 
 [3] 12 9 (aorta tissue) 6/6 (100) 12/12 (100)             0/9 (0) 
[13] 41  0a 17/41 (41)  
[22] 20 0a 0/20 (0)  
[23] 19 0a 0/19 (0) 19/19 (100) 
[24] 11 0a   6/11 (55) 
[25] 40 40 (aorta tissue) 14/40 (35)            2/40 (5)  
[26] 51 0a 26/51 (51)  
[27] 25 6 (vascular tissue) 11/25 (44)            3/6 (50)  
aNo controls were included in the study; PCR, polymerase chain reaction; IHC, 
immunohistochemistry. 
 
The pathogenesis of AAA is unknown. There is some evidence that genetic factors, familial 
clustering and several proteolytic factors are involved in the pathogenesis [2, 33]. C. 
pneumoniae may directly cause endothelial injury. It also might induce a chronic 
immunological activation, causing chronic endothelial cell damage and mediating a 
proteolytic process in the wall of the abdominal aorta [3, 34]. Similarly, it has been suggested 
that chlamydial lipopolysaccharide and chlamydial heat-shock protein 60 may promote 
atherogenesis by inducing mononuclear phagocyte foam cell formation and mononuclear 
phagocyte oxidation of low-density lipoprotein, respectively [35].  
In conclusion, the results of our study indicate that C. pneumoniae is associated with AAA. 
Although a causal relationship was not established, our results provide additional evidence 
that the role of C. pneumoniae needs to be explored further for better understanding of the 
pathogenesis of AAA. 
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Abstract 
We assessed the impact of five serologic tests on the link between Chlamydia pneumoniae 
and abdominal aortic aneurysm (AAA). The results of the tests were inconsistent. Agreement 
among the five tests was generally poor. Detection of the link between C. pneumoniae and 
AAA depends on the serologic methodology chosen. 
 
Introduction 
Seroepidemiologic studies that had investigated the link between Chlamydia pneumoniae and 
vascular diseases reported inconsistent results, ranging from a strong link to no link at all [3]. 
This discrepancy might be due to methodological factors [15]. Two recent studies have 
demonstrated that the detection of a link between C. pneumoniae and coronary artery disease 
depends on the choice of serologic methods [6, 15]. The serologic link between C. 
pneumoniae and vascular diseases has been assessed by microimmunofluorescence (MIF) 
tests and enzyme-linked immunosorbent assays (ELISA). However, these serologic tests lack 
sufficient reliability and standardization [4]. A poor agreement among the results of these 
tests has been reported [6, 13, 15].  
In this case-control study, we investigated whether the choice of serologic tests influences 
the detection of a link between C. pneumoniae and abdominal aortic aneurysm (AAA). 
Moreover, we evaluated the agreement among the results of these tests. 
 
Materials and Methods, Results and Discussion 
The study population was previously described [9]. Patients with AAA and healthy controls 
were included and matched by age and sex. Serum samples were tested for the presence of C. 
pneumoniae IgG antibodies by five serologic tests, i.e., Chlamydia MIF IgG (MRL 
Diagnostic), Chlamydia IgG SeroFIA (Savyon Diagnostics Ltd; Savyon-MIF), Chlamydia 
IgG rELISA Medac (Medac Diagnostica), SeroCP IgG (Savyon Diagnostics Ltd; Savyon-
ELISA), Elegance Chlamydia pneumoniae IgG ELISA (Bioclone). 
The MRL-MIF uses, as the antigen, purified C. pneumoniae (strain TW 183) elementary 
bodies (EB) diluted in 3% yolk sac to add contrast to the background. According to the 
manufacturer’s product information, the EBs are purified by removing the genus-specific 
lipopolysaccharide (LPS). The Savyon-MIF and the Savyon-ELISA also use purified C. 
pneumoniae (strain TW 183) EB as the antigen. The Medac-rELISA uses a recombinant LPS-
fragment as the antigen. For the Bioclone-ELISA, purified C. pneumoniae outer membrane 
protein complexes are used as the antigen. All tests were performed and interpreted in a 
blinded fashion by the same technician, according to the manufacturers’ instructions. 
We used odds ratios and a 95% confidence interval for estimating the relative risk. Kappa 
(κ) values were used to assess the agreement among the tests. The following guidelines were 
used in the interpretation of κ: if κ was <0.2, agreement was poor, if κ was 0.21 to 0.4, 
agreement was fair, if κ was 0.41 to 0.6, agreement was moderate, if κ was 0.61 to 0.8, 
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agreement was good, and if κ was 0.81 to 1.0, agreement was very good [1]. P values of 
<0.05 were considered statistically significant. 
The study population included 88 patients with AAA and 88 healthy controls. The 
characteristics of the study population are shown in table 1. The results of the five tests were 
inconsistent (table 2). In the patient group, seropositivity rates varied from 52% (46 of 88) 
with the Medac-rELISA to 97% (85 of 88) with the MRL-MIF. In the healthy controls, a 
similar variation was found: 55% (48 of 88) were positive with the Medac-rELISA compared 
to 97% (85 of 88) with the Bioclone-ELISA. 
 
 
Table 1. Baseline characteristics of patients with AAA and control subjectsa 
Characteristic No. of AAA 
patients 
No. of control 
subjects 
P value 
Age (yr) (range)  69 (45-85) 67 (44-83) NS c 
Male/female 81/7 81/7 NS 
Aneurysm    
  Under control 35   
  Operated 53   
  Elective                       40   
  Symptomatic   7   
  Ruptured   6   
  Family history of aneurysm 16   9 NS 
History    
  Myocardial infarction 26   9 <0.01 
  Cerebrovascular disease   9   4 NS 
  Pulmonary embolism   2   3 NS 
  Chronic obstructive pulmonary disease 24 13 NS 
  Peripheral vascular disease 19   4 <0.01 
  Diabetes mellitus   6   4 NS 
Smoking    
  Pack-yr of cigarette smokingb (±SD) 34 (±33) 23 (±22) <0.01 
Medication    
  Antihypertensive drugs   48   28 <0.01 
  Cholesterol-lowering drugs   28    8 <0.001 
  Nonsteroidal anti-inflammatory drugs   37  17 <0.01 
Mean systolic blood pressure, mmHg (SEM) 159 (2.4) 158 (2.6) NS 
Mean diastolic blood pressure, mmHg (SEM)   85 (1.2)   87 (1.2) NS 
Mean cholesterol, mmol/l (SEM)    5.7 (1.13)    5.7 (0.10) NS 
a Patients (n = 88) and controls (n = 88) were matched by age and sex; b A pack-year was defined as 
smoking 20 cigarettes/day for 1 year; c NS, not significant. 
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The MRL-MIF was the only test that demonstrated a significant link between C. 
pneumoniae and AAA. The other four tests failed to demonstrate any link. However, the 
MRL-MIF also failed to demonstrate a link when higher IgG titers were used as cutoffs. 
Although the results of the two MIF used in our study were read by the same technician, 
there was poor agreement between the two tests. This implies that in addition to the subjective 
reading of MIF results, other factors may contribute to disagreement among results of C. 
pneumoniae serologic tests. The test procedure, the type of antigen, the antigen’s purity, and 
the concentration of the antigen may also account for poor agreement among the results of 
these serologic tests [5]. The link between low titers of C. pneumoniae IgG and AAA, 
demonstrated by the MRL-MIF, might be the result of a cross-reaction to the antigen used in 
the test from sources other than C. pneumoniae [8]. These sources, either infectious or 
noninfectious, might be associated with AAA and confound the association between C. 
pneumoniae and AAA. 
 
Table 2. Association between C. pneumoniae seropositivity and AAA according to five different testsa 
Test IgG titer or 
index value 
No. of AAA 
patients  
No. of control 
subjects 
Odds ratio (95% 
confidence interval) 
MRL-MIF - IgG> 1:16             
- IgG> 1:512 
85 
24 
71 
21 
6.8 (2.0-24.1) 
1.2 (0.6-1.8) 
Savyon-MIF            - IgG> 1:64 
- IgG> 1:512 
79 
21 
79 
20 
1.0 (0.4-2.7) 
0.9 (0.5-1.8) 
Medac-rELISA           - IgG> 1:100           
- IgG> 1:400 
46 
23 
48 
18 
0.9 (0.5-1.7) 
1.4 (0.7-2.8) 
Savyon-ELISA b - index> 1.10 67 71 0.8 (0.4-1.6) 
Bioclone-ELISA c  - index> 1.10          
- index >3.0 
84 
20 
85 
16   
0.7 (0.2-3.4) 
1.3 (0.6-2.8) 
a Eighty-eight patients and 88 controls were tested. b For the Savyon-ELISA, high titers were not 
found. c According to test kit instructions, an index value of >3 corresponds to an IgG titer of > 1:512. 
 
 
The agreement among the results obtained by the five serologic tests was generally poor 
(table 3). Inter- and intralaboratory variations and a poor agreement among results of 
serologic tests of C. pneumoniae have also been demonstrated by others [6, 13, 15]. Ranges of 
agreement from 59% to 90% have been reported [13, 15]. Hoymans et al. [6] found poor 
agreement between results of the MIF and the Medac-rELISA, but three other ELISA showed 
moderate to good agreement in results with the MIF [6]. 
There is evidence that C. pneumoniae serologic tests are less specific than previously 
realized [5, 8, 11]. Cross-reactivity between C. pneumoniae and Chlamydia species in the 
MIF has been demonstrated [8, 11]. This is probably due to a lack of LPS removal from the 
EB during antigen preparation [11]. It is also possible that Chlamydia-like microorganisms, 
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Bordetella pertusis and parvovirus cause serologic antigenic cross-reactivity with C. 
pneumoniae [6, 7, 10, 12, 14]. 
Our results support the findings of recent studies which have shown that methodology has 
an important impact on whether a link is found between C. pneumoniae and vascular diseases 
[6, 15]. This indicates that methodological factors are partly responsible for the conflicting 
results in the literature concerning the role of C. pneumoniae in the development of vascular 
diseases [2, 3]. 
This study shows that the detection of a serologic link between C. pneumoniae and AAA 
depends on which test is used to measure C. pneumoniae antibodies. Further studies should 
focus on optimizing and standardizing C. pneumoniae serologic methods. 
 
Table 3. Agreement of κ values between the serological results of the five different tests for the patient 
group and the healthy controls  
   κ valuea   
Group          Test IgG titer or 
index value 
Savyon-
MIF 
Medac-
rELISA 
Savyon-
ELISA 
Bioclone-
ELISAb 
Patients       MRL-MIF  IgG> 1:16 0.12 0.02 0.14 0.55 
                    Savyon-MIF IgG> 1:64  0.12 0.45 0.42 
                    Medac-rELISA IgG> 1:100   0.09 0.05 
                    Savyon-ELISA index>1.10    0.26 
      
Controls      MRL-MIF  IgG> 1:16 0.11 0.06 0.12 0.25 
                    Savyon-MIF IgG> 1:64  0.09 0.55 0.47 
                    Medac-rELISA IgG> 1:100   0.15 0.08 
                    Savyon-ELISA index>1.10    0.25 
 a κ expresses the agreement between the tests regarding nominal scale variables (positive and negative 
results). b The Bioclone-ELISA had an index value of >1.10. 
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Abstract  
Inflammatory mediators are involved in activation of the coagulation system, and elevated 
plasma concentrations of IL-6 and IL-8 are associated with an increased risk of venous 
thrombosis. Using serologic and molecular biologic tests, we investigated in a case-control 
study on patients with recurrent venous thrombosis the association between Chlamydia 
pneumoniae and venous thrombosis and we evaluated the relation between C. pneumoniae 
serology and the cytokines IL-6 and IL-8. The presence of C. pneumoniae antibody titers ≥ 
1:16 was not associated with an increased risk of venous thrombosis (odds ratio 0.8 95% CI, 
0.4-1.7). Circulating C. pneumoniae DNA was detected in only one patient and two control 
subjects. IgG antibody titers against C. pneumoniae were not correlated with the 
concentrations of IL-6 and IL-8. These results indicate that the inflammatory process shown 
in patients with venous thrombosis is not related to C. pneumoniae. 
 
Introduction  
Venous thrombosis is a multicausal disease and several genetic and acquired risk factors have 
been identified [5, 13]. Recently we have shown that elevated plasma concentrations of IL-6 
and IL-8 are associated with an increased risk of venous thrombosis [14]. However, the cause 
of these elevated cytokine concentrations remains unknown. 
Infections with Chlamydia pneumoniae have drawn many attention as risk factor for 
cardiovascular disease. It has been demonstrated that acellular components of C. pneumoniae 
stimulate the production of cytokines in blood mononuclear cells and induce cytokines 
production [6, 11]. So, it can be hypothesized that infection with C. pneumoniae is also a risk 
factor for venous thrombosis and that explains the elevated cytokine levels in patients with 
venous thrombosis. 
Recently, two controversial reports have been published on the association between venous 
thrombosis and the serology of C. pneumoniae. Lozinguez et al. [8], reported IgG antibodies 
against C. pneumoniae a risk factor of venous thromboembolism using 
microimmunofluorescence (MIF) test. This finding was not supported by Koster et al. [7], 
who found no increased risk of deep-vein thrombosis in relation with elevated antibody titers 
against C. pneumoniae. However, they did not use the reference serologic method (MIF test) 
to measure antibodies against C. pneumoniae. Therefore, we questioned whether their results 
are a reliable parameter of C. pneumoniae infection [9].  
In the current study, we investigated, in a case-control study, whether C. pneumoniae is 
associated with an increased risk for venous thrombosis, using serologic and molecular 
biologic tests. Furthermore, we investigated the relationship between C. pneumoniae serology 
and the concentrations of the cytokines IL-6 and IL-8.  
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Materials and Methods 
The study population has been previously described in detail [2]. Briefly, 473 patients with 
two or more episodes of venous thrombosis from the files of the anticoagulant clinic of The 
Hague, The Netherlands, were approached, and 185 participated. The healthy control group 
was selected through a general practice in The Hague. From the 2812 approached subjects 
532 subjects were ready to participate in the study, and the first 220 formed the control group. 
Specimens were collected throughout the year.  
 
C. pneumoniae IgG antibodies   
IgG antibodies against C. pneumoniae (TW 183), in the sera of patients and controls, were 
measured using a MIF test (MRL, Cypress, Ca, USA) as described previously [3, 12]. 
Samples were tested at a dilution of 1:16. Positive samples were tested at a dilution of 1:32, 
1:64, 1:128, 1:256, and 1:512. Samples were coded and the code number was revealed 
following the completion of all laboratory tests. All serologic tests were performed blind by 
the same technician. An IgG antibody titer > 1:16 was considered as positive serology.  
 
Polymerase chain reaction (PCR) 
Buffy-coat samples were prepared by centrifuging EDTA-whole blood 3300 gX for 10 min. 
PCR samples were prepared by extracting C. pneumoniae DNA from 200 µL of the buffy-
coat fraction using the QIAamp DNA minikit (Qiagen, Hilden, Germany). Detection of C. 
pneumoniae DNA was performed using a validated PCR assay as described previously [4]. 
The primers CpnA (5’-TGA CAA CTG TAG AAA TAC AGC-3’) and CpnB (5’-CGC CTC 
TCT CCT ATA AAT-3’) were used in a PCR assay based on the sequence of the 16S rRNA 
gene. A negative control, containing all PCR reagents without specimens, was processed with 
every 5 samples. To control for inhibition of the PCR reaction, a second sample of each buffy-
coat sample was spiked with C. pneumoniae target DNA. If the spiked sample was negative 
the sample was considered inhibited. Inhibited PCR samples were repurified and retested 
using 2.5 µL of specimen. To minimize the risk of contamination, sample processing and the 
PCR assay were performed in separate rooms, and to prevent carryover of previous PCRs 
UDG/dUTP were used. PCR products were visualized after electrophoresis in 2% ethidium 
bromide- stained agarose gels. To confirm positive results, 3 µL of the PCR product was 
spotted and hybridized with a 21 bp 5’-biotinylated probe Cpneu-B (5’-GAC ACA CGT ACA 
ATG GTT-3’). Hybridization signals were visualized using streptavidin-peroxidase and 
enhanced-chemiluminescence (ECL) detection reagents (Amersham, Little Chalfont, United 
Kingdom). 
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Inflammatory mediators 
As described previously [14], plasma levels of IL-6 and IL-8 were measured using a 
commercial ELISA (Central Laboratory of the Netherlands Red Cross Blood Transfusion 
Service CLB, Amsterdam, the Netherlands). The ELISA tests were performed blind. The 
detection limit for the ELISA was 1.2 pg/ml for IL-6 and 2.0 pg/ml for IL-8. Samples below 
the detection limit were designated as 0 pg/ml. 
 
Statistical analysis   
Odds ratios and 95% confidence interval were calculated as an estimate of the relative risk for 
recurrent venous thrombosis by means of logistic regression analysis and are adjusted for age 
and sex.  
 
Results 
The mean age of the patients and the control subjects was 61 years (range 23 to 88) and 51 
years (range 21 to 84), respectively. The cases group consisted of 94 males and 91 females, 
and the control group 94 males and 126 females.  
Serum for C. pneumoniae serology was available from 184 cases and 218 control subjects. 
Plasma concentration of IL-6 was available from 181 cases and 163 control subjects. Plasma 
concentration of IL-8 was available from 168 cases and 148 control subjects. Because 
samples were initially collected to evaluate the association between venous thrombosis and 
hyperhomocysteinemia and many assays were performed in that study [2], some samples were 
used up and were not more available for all assays in the present study. 
The prevalence of seropositivity to C. pneumoniae was quite similar in patients and control 
subjects 91% and 92%, respectively. Table 1 shows the odds ratio at different cut-off for the 
IgG titer to C. pneumoniae. The odds ratio (adjusted for age and sex) for positive IgG titer (> 
1:16) was 0.8 (95% CI, 0.4-1.7). This indicates that antibody titer against C. pneumoniae is 
not a risk factor for venous thrombosis.  
 
Table 1. Chlamydia pneumoniae IgG antibody titers and the risk of venous thrombosis  
IgG titer No. of  
case subjects 
No. of  
control subjects  
Odds Ratio (95% CI) 
(adjusted for age and sex) 
Negative  17  18 1* 
> 1:16 167 200 0.8 (0.4 – 1.7) 
> 1:32 149 185 0.8 (0.5 – 1.4) 
> 1:64 139 174 0.9 (0.5 – 1.5) 
> 1:128 118 141 1.1 (0,7 – 1.7) 
> 1:256  72  95 0.8 (0.5 – 1.2) 
> 1:512  40  63 0.6 (0.4 – 1.0) 
* Reference category. 
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Figures 1-4 show the correlation between the IgG titers and the concentrations of IL-6 and 
IL-8. There was no clear difference in IL-6 and IL-8 levels in subjects with or without 
positive C. pneumoniae titer. However, a few subjects with high levels of IL-6 or IL-8 (>20 
pg/ml) were all seropositive (9 and 5, respectively).  
Circulating C. pneumoniae DNA was detected by PCR in one patient (0.5%) and two 
control subjects (0.9%).  
 
Figure 1. The relation between IL-6 concentration and IgG antibody titer against 
Chlamydia pneumoniae  in control subjects.
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Figure 2. The relation between IL-8 concentration and IgG antibody titer against 
Chlamydia pneumoniae  in control subjects.
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Figure 3. The relation between IL-6 concentration and IgG antibody titer against 
Chlamydia pneumoniae  in patients with recurrent venous thrombosis.
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Figure 4. The relation between IL-8 concentration and IgG antibody titer against 
Chlamydia pneumoniae  in patients with recurrent venous thrombosis.
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Discussion 
The results of the present study show that C. pneumoniae as detected by serology or PCR of 
peripheral blood cells is not associated with increased risk of venous thrombosis. 
Furthermore, IgG antibody titers against C. pneumoniae were in general not correlated with 
the concentrations of IL-6 and IL-8, although high levels of these cytokines were especially 
found in subjects with positive serology for C. pneumoniae. These results indicate that the 
inflammatory process shown in patients with venous thrombosis is not related to C. 
pneumoniae infection. 
The studies of Lozinguez et al. [8] and Koster et al. [7] produced controversial results. 
Lozinguez et al. [8] demonstrated that C. pneumoniae seropositivity is correlated with an 
increased risk for deep-vein thrombosis. Koster et al. [7] did not find any association between 
C. pneumoniae serologic status and venous thrombosis. The negative results might be 
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explained by the fact that Koster et al. have used an Elisa test for antibody detection, which is 
not the standard method [9]. However, in the present study using the standard MIF test to 
measure IgG antibodies to C. pneumoniae, we didn’t find any association too. 
Respiratory infection with C. pneumoniae occurs more frequently in winter. Our study was 
performed throughout the year. Although the patients where enrolled especially during winter 
and the control subjects in autumn, one would expect higher prevalence in the patients group, 
which was not found. This implies that the findings of the present study were not biased by a 
season effect. Moreover, the control group is recruited from the general population in the 
same area as the patient group, so we think it is an appropriate control group. 
Next to serology, we studied the detection of C. pneumoniae DNA in peripheral blood cells 
of patients with venous thrombosis, which has not been reported before. The detection rate of 
C. pneumoniae DNA was very low in patients with recurrent venous thrombosis as well as in 
control subjects. In a previous study [10], using the same PCR assay, we detected C. 
pneumoniae DNA in peripheral blood cells of 9% (8/88) of the healthy control subjects. An 
explanation for the difference in the detection rate between the present study and our previous 
study might be that the current study population is somewhat younger compared to the control 
subjects which were age-matched to patients with abdominal aneurysm. Furthermore, the 
reproducibility of C. pneumoniae PCR assays might be less than generally believed. A recent 
multicenter study showed major inter-laboratory differences in detection rate of C. 
pneumoniae in endarterectomy specimens [1].  
Our data show that C. pneumoniae is not associated with an increased risk for venous 
thrombosis and show that C. pneumoniae does not explain the chronic inflammation 
associated with venous thrombosis. Thrombosis should be considered as a possible cause of 
the increase of cytokines in patients with venous thrombosis. This emphasizes the need for 
further studies to assess the mechanisms by which inflammatory markers are elevated in 
venous thrombosis. 
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Abstract 
Polymerase chain reaction (PCR) and immunohistochemistry (IHC) have been used to detect 
Chlamydia pneumoniae in vascular tissues. Discrepancies between the results of these two 
methods have frequently been reported. However, the correlation between PCR and IHC has 
not been analyzed yet. This study assesses the correlation between the detection of C. 
pneumoniae by PCR and IHC in 45 atherosclerotic and 50 non-atherosclerotic tissue 
specimens. Also, the presence of Mycoplasma pneumoniae in these 95 specimens was 
investigated. Correlation was found between the detection of C. pneumoniae by PCR and IHC 
in the atherosclerotic tissues. Both tests were positive in 10 specimens and negative in 17 
specimens (p = 0.003). There was no significant correlation between PCR and IHC in non-
atherosclerotic specimens (p = ns). M. pneumoniae was detected, by PCR, in one 
atherosclerotic specimen. The results show correlation between PCR and IHC in the detection 
of C. pneumoniae in atherosclerotic tissues, emphasize the association between C. 
pneumoniae and atherosclerosis, and support the specificity of the association between C. 
pneumoniae and atherosclerosis. 
 
Introduction  
Using polymerase chain reaction (PCR) and immunohistochemistry (IHC), the presence of 
Chlamydia pneumoniae has been demonstrated in atherosclerotic tissues, but in control 
vascular tissues this pathogen has been found less frequently [28]. These findings indicate that 
C. pneumoniae may play a role in the pathogenesis of atherosclerosis.  
In addition to C. pneumoniae, several micro-organisms have been postulated as possible risk 
factors for atherosclerosis [5, 27]. The association between atherosclerosis and both 
cytomegalovirus and Helicobacter pylori has been extensively studied [5]. However, till now 
only one report on the presence of Mycoplasma pneumoniae in vascular tissues has been 
generated [23].  
The microimmunofluorescence test (MIF), PCR and IHC have been used to explore the 
association between C. pneumoniae and atherosclerosis. Discrepancies among the results 
obtained by these methods have frequently been found [9, 11, 15]. Nothing, however, is 
known about the correlation between the results of these detection methods.  
The present study assesses the correlation between the detection of C. pneumoniae by PCR 
and IHC. Also, the correlation between C. pneumoniae serology and the detection of this 
pathogen, by PCR and IHC, in vascular tissue specimens was analyzed. M. pneumoniae-PCR 
was performed to detect M. pneumoniae in atherosclerotic and non-atherosclerotic tissues.  
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Materials and methods 
Specimens were collected from 95 patients undergoing cardiac surgery. Forty-five 
atherosclerotic specimens and 50 non-atherosclerotic tissue specimens (aortic-punchs) were 
collected. Each specimen was divided into two portions; one for PCR and one for IHC. The 
PCR portion was transported to the laboratory in a Tris-EDTA buffer containing 0.5% sodium 
dodecyl sulfate. In the laboratory, specimens were stored at -20oC. The IHC portion was fixed 
in 10% phosphate-buffered formalin. In addition, sera were obtained from all patients to 
measure IgG antibodies to C. pneumoniae. Specimens were evaluated blind. Patients were not 
examined to assess the presence of C. pneumoniae clinical disease. 
 
Polymerase chain reaction 
DNA extraction from specimens was performed using the QIAamp DNA minikit (Qiagen, 
CA, USA). For the PCR template, 5 µL of 200 µL elution sample was used.  
Detection of C. pneumoniae DNA was carried out by 16S rRNA gene-based PCR, using the 
primers CpnA: 5’-TGA CAA CTG TAG AAA TAC AGC-3’ and CpnB: 5’-CGC CTC TCT 
CCT ATA AAT-3’ as described previously [8].  
Detection of M. pneumoniae was performed by PCR assay based on the P1 adhesin gene 
using the primers Pn1: 5’-GCC ACC CTC GGG GGC AGT CAG-3’ and Pn2: 5’-GAG TCG 
GGA TTC CCC GCG GAG G-3’ as described previously [10, 23]. 
To minimize the risk of contamination, strict PCR-anti-contamination precautions, such as 
the use of UDG/dUTP, were taken to prevent carry-over of previous PCR reactions. Sample 
processing and PCR assays were performed in separate rooms and a negative control was 
processed with every 5 samples. To control for inhibition of the PCR reaction, a second 
sample of each specimen was spiked with target DNA (C. pneumoniae or M. pneumoniae). 
Inhibited PCR samples were retested using 2.5 µl of specimen. PCR products were visualized 
after electrophoresis in 2% ethidium bromide-stained agarose gels.  
To confirm positive results, 3 µl of the PCR product was spotted and hybridized, with the 21 
bp 5’-biotinylated probe Cpneu-B:5’ GAC ACA CGT ACA ATG GTT-3’ in the case of C. 
pneumoniae-PCR and with the 5’-biotinylated probe MP2-B: 5’-GGT GAA GGA ATG ATA 
AGG CT-3’ in the case of M. pneumoniae-PCR. Hybridization signals were visualized using 
streptavidin-peroxidase and ECL detection reagents (Amersham, UK). 
 
Immunohistochemistry   
Specimens were transported in 10% phosphate buffered formalin. Subsequently tissues were, 
in some cases after decalcification with EDTA, embedded in paraffin and sectioned at 5 µm. 
IHC staining was performed according to methods previously described [16]. Sections were 
stained with a mouse anti-C. pneumoniae (TW 183) monoclonal antibody (DAKO 
Diagnostics, Denmark). C. pneumoniae-infected HL cells and a tissue section stained with 
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normal mouse ascites were used as a positive and a negative control, respectively. Positive 
and negative controls were run with each batch of specimens. 
 
Microimmunofluorescence test  
C. pneumoniae (TW 183) IgG antibodies in the sera were determined using a MIF test (MRL 
Diagnostics, CA) as described previously [7, 24]. An IgG antibody titer > 1:16 was 
considered positive. All serologic tests were performed blind by the same technician.  
 
Statistical analysis  
Correlation between the results of the different assays was analyzed by the Cohen’s Kappa 
test.  
 
Results 
Atherosclerotic specimens were obtained from 38 males and 7 females (mean age 63 years, 
range 41-86). Non-atherosclerotic lesions were obtained from 41 males and 9 females (mean 
age 65 years, range 44-79). 
Forty-five atherosclerotic tissue specimens and 50 non-atherosclerotic tissue specimens 
were available for the PCRs assays. Specimens for IHC assay were obtained from all patients, 
but 3 atherosclerotic specimens and 4 non-atherosclerotic specimens were missed. Blood 
samples for C. pneumoniae serology were available from 91 patients (41 in the atherosclerotic 
group and 50 in the non- atherosclerotic).  
C. pneumoniae DNA was detected by PCR in 22% (10/45) of atherosclerotic specimens and 
in 10% (5/50) of non- atherosclerotic specimens. IHC staining was positive for C. 
pneumoniae in 60% (25/42) of the atherosclerotic specimens and in 9% (4/46) of the non-
atherosclerotic specimens. The correlation between the detection of C. pneumoniae by PCR 
and IHC is shown in table 1. There was a correlation between the detection of C. pneumoniae 
by PCR and IHC in atherosclerotic specimens (p = 0.003). A poor correlation was found 
between the results obtained by PCR and IHC in non-atherosclerotic specimens (p = NS).  
 
Table 1. Correlation between polymerase chain reaction (PCR) and immunohistochemistry (IHC) in 
the detection of C. pneumoniae in atherosclerotic and non-atherosclerotic tissue specimens 
 atherosclerotic specimens non-atherosclerotic specimens 
 IHC negative IHC positive IHC negative IHC positive 
PCR negative, no. 17 15 38 4 
PCR positive, no.  0 10  4 0 
Correlation, Kappa (p)        0.35 (0.003)              0.1  (ns) 
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The MIF test detected C. pneumoniae IgG antibodies in 88% (36/41) of patients in the 
atherosclerotic group and in 96% (48/50) of patients in the non- atherosclerotic group. Table 2 
demonstrates the correlation between C. pneumoniae serology and the results obtained by 
either PCR or IHC. There was no significant correlation between C. pneumoniae serology and 
both PCR and IHC.  
M. pneumoniae was detected by PCR in one atherosclerotic tissue specimen. All non-
atherosclerotic specimens were M. pneumoniae-negative. 
 
Table 2. Correlation between serology (MIF), polymerase chain reaction (PCR) and 
immunohistochemistry (IHC) 
Atherosclerotic specimens    
 PCR negative PCR positive IHC negative IHC positive 
MIF negative, no.   5   0   2   2 
MIF positive, no. 26 10 12 22 
Correlation, Kappa, (p)              0.1 (ns)           0.07 (ns) 
Non-atherosclerotic specimens    
 PCR negative PCR positive IHC negative IHC positive 
MIF negative, no.   1  1  2  0 
MIF positive, no. 44  4 40  4 
Correlation, Kappa, (p)             0.04 (ns)           0.01 (ns) 
 
 
Discussion 
This study shows the following features: there was correlation between PCR and IHC in the 
detection of C. pneumoniae in atherosclerotic tissues, but a poor correlation was found in non-
atherosclerotic specimens. The MIF test was not correlated with the results of PCR and IHC. 
M. pneumoniae was detected in one atherosclerotic specimen. All non-atherosclerotic 
specimens were M. pneumoniae-negative. 
Several studies have reported a wide variation in the detection rate of C. pneumoniae 
between PCR and IHC [9, 15]. In general, more positive results are obtained with IHC than 
PCR. This was also the case in the present study. It has been suggested that these 
discrepancies might reflect differences in the sensitivity and specificity of these two methods 
[28]. Focal localization of C. pneumoniae in vascular tissues and the presence of components 
that inhibit PCR may influence the results of IHC and PCR [15]. However, discrepancy 
between detection rates of C. pneumoniae by PCR and IHC does not imply that there is no 
correlation between these methods. In this study, with regard to the atherosclerotic tissues 
there was correlation between the results of IHC and PCR, but no such correlation was found 
in non-atherosclerotic specimens. We can not explain why no correlation was found in non-
atherosclerotic tissues. A poor correlation may be due to the relatively small number of 
specimens tested and to the low positive rate by PCR and IHC in the non-atherosclerotic 
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specimens. A possible explanation for this is that after initial infection, C. pneumoniae does 
not persist in non-atherosclerotic tissues [11].  
We analyzed the correlation between PCR and IHC in 10 studies in which these methods 
were used to detect C. pneumoniae in arterial tissues [4, 6, 11, 12, 14, 17, 18, 19, 25, 26]. 
Correlation between PCR and IHC results was found in 7 studies (table 3). Our findings 
together with previous reports provide evidence that the results of PCR and IHC are 
correlated in atherosclerotic tissues. This finding emphasizes the association between C. 
pneumoniae and atherosclerosis, and provides an additional histological evidence that 
supports the hypothesis that C. pneumoniae might be involved in the pathogenesis of 
atherosclerosis. 
 
Table 3. Correlation between polymerase chain reaction (PCR) and immunohistochemistry 
(IHC) in 10 studies in which arterial tissues were investigated 
Reference Material No. PCR+ a 
& IHC+ 
PCR-b  
& IHC- 
PCR+ 
& IHC- 
PCR-  
& IHC+ 
Correlation, 
Kappa (p) 
  [4] Coronary atheromas 38  9 18 3 8 0.4 (0.01) 
[11] Coronary arteries 38  1 25 5 7 0.05 (0.8) 
[17] Coronary atheromas 30  8 14 5 3 0.45 (0.01) 
[26] Arterial atheromas  7  2  4 0 1 0.7 (0.05) 
[19] Peripheral arteries 17  2  9 0 6 0.3 (0.1) 
[14] AAA c  9  5  3 1 0 0.8 (0.02) 
[12] Carotid endarterectomy 16  3  8 0 5 0.4 (0.055) 
[25] Coronary arteries 12  3  5 2 2 0.3 (0.3) 
[18] Coronary arteries 49  2 41 1 5 0.3 (0.007) 
  [6] Coronary arteries 60 12 38 2 8 0.6 (<0.001) 
a + Positive; b – Negative; c AAA; abdominal aortic aneurysm. 
 
In the present study no correlation was found between C. pneumoniae serology and the 
detection of C. pneumoniae either by PCR and IHC. Controversial reports have been 
published on the association between C. pneumoniae serology and the detection of this 
pathogen in vascular tissues [1]. We analyzed 7 studies in which C. pneumoniae IgG 
antibodies were determined and PCR was used to detect C. pneumoniae in arterial tissues [2, 
3, 13, 17, 20-22]. Correlation between PCR and serological results was found in 3 studies 
(table 4). 
Large differences in detection rate of C. pneumoniae between atherosclerotic lesions and 
non-atherosclerotic controls have been reported, 51% (303 of 597 specimens) and 4% (5 of 
131 specimens), respectively [9]. This is consistent with the results of the present study, since 
C. pneumoniae was more frequently detected in atherosclerotic tissues than non-
atherosclerotic tissues. It has been suggested that C. pneumoniae might be less frequently 
disseminated to non-atherosclerotic tissues or it does not persist for a long time in these 
tissues [11]. 
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Table 4. Correlation between PCR and serology (MIF) in 7 studies in which arterial tissues were 
investigated 
Reference Material No. PCR+ a  
& MIF+ 
PCR -b 
& MIF- 
PCR+  
& MIF- 
PCR-  
& MIF+ 
Correlation 
Kappa, (p) 
[17] Coronary atheromas  29  8  2 5  14 0.2 (0.1) 
[21] Coronary arteries 158 34 24 0 100 0.1 (0.005) 
  [2] AAAc  51 25  9 1  16 0.3 (0.004) 
[22] Carotid endarterectomy 
& restenotic bypass 
 70 21  2 0  47 0.03 (0.3) 
[20] Carotid endarterectomy  47  7  8 0  32 0.07 (0.2) 
  [3] AAA  41 16 14 1  10 0.3 (0.01) 
[13] Coronary atheromas  40  2 16 1  21 0.02 (0.7) 
a + Positive; b - Negative; c AAA; abdominal aortic aneurysm. 
 
In a previous study, we detected M. pneumoniae in one of 39 atherectomy specimens and in 
two of 64 degenerative heart valves [23]. In the present study, we simultaneously performed 
C. pneumoniae- and M. pneumoniae-PCR on atherosclerotic and non-atherosclerotic tissues. 
One atherosclerotic specimen was positive in the M. pneumoniae-PCR, and 15 specimens (10 
atherosclerotic and 5 non-atherosclerotic) were positive in the C. pneumoniae-PCR. These 
results add a new evidence for the specificity of the association between C. pneumoniae and 
vascular disease.   
In conclusion, the results of this study show a good correlation between PCR and IHC in the 
detection of C. pneumoniae in atherosclerotic tissues. This supports the association between 
C. pneumoniae and atherosclerosis and indicates that C. pneumoniae might be involved in the 
development of atherosclerosis. The very low detection rate of M. pneumoniae in 
atherosclerotic specimens supports the specificity of the association between C. pneumoniae 
and atherosclerosis. 
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Introduction 
Several studies have postulated a link between infectious agents and atherosclerosis [3, 12]. 
Epidemiological and pathological studies have shown an association between Chlamydia 
pneumoniae and atherosclerosis [3, 12]. C. pneumoniae has been detected in vascular tissues 
and degenerative heart valves [3, 9]. It has been suggested that Mycoplasma pneumoniae 
might also play a role in the development of atherosclerosis [12]. Myocarditis, pericarditis, 
cerebral stroke, and vasculitis have been previously associated with M. pneumoniae infection 
[1, 4, 5, 11]. M. pneumoniae might be seen as a plausible candidate to play a role in the 
pathogenesis of atherosclerosis, because it has been related to cardiovascular disease and its 
ability to induce chronic inflammation [12]. Taylor-Robinson and Thomas have postulated 
that there is a need to investigate the presence of M. pneumoniae in vascular tissues, because 
there is a similarity in epidemiological behavior and antibiotic susceptibility between M. 
pneumoniae and C. pneumoniae [12]. Furthermore, M. fermentans has been detected in 1 of 19 
human arterial specimens that were positive for C. pneumoniae [10], and it has been shown 
that M. gallisepticum exhibits tropism for arterial tissue in turkeys [2]. However, nothing is 
known about the presence of M. pneumoniae in human atherosclerotic vascular tissues. 
Therefore, we investigated the presence of M. pneumoniae in atherectomy specimens and in 
degenerative heart valve (DHV) specimens. 
 
Materials and Methods, Results and Discussion 
Atherectomy specimens (n = 39) and DHV specimens (n = 64) were obtained from patients 
undergoing cardiac surgery for coronary artery bypass graft surgery and heart valve 
replacement, respectively. Specimens were transported in a Tris-EDTA buffer containing 
0.5% sodium dodecyl sulfate. DNA extraction was performed using a commercial kit 
(QIAamp DNA Minikit; Qiagen, Hilden, Germany). Detection of M. pneumoniae was 
performed by a PCR assay based on the P1 adhesin gene and using the primers Pn1 (5'-GCC 
ACC CTC GGG GGC AGT CAG-3') and Pn2 (5'-GAG TCG GGA TTC CCC GCG GAG G-
3') as described previously [7]. PCR products were visualized after electrophoresis in 2% 
ethidium bromide-stained agarose gels (Fig. 1). To confirm the PCR results, the PCR product 
was spotted and hybridized with the 5'-biotinylated probe MP2-B (5'-GGT GAA GGA ATG 
ATA AGG CT-3'). Hybridization signals were visualized using streptavidin-peroxidase and 
enhanced chemiluminescence (ECL) detection reagents (Amersham, Little Chalfont, United 
Kingdom).  
M. pneumoniae was detected in only 1 (2.5%) of the 39 atherectomy specimens and in 2 
(3%) of the 64 DHV specimens. This is the first study on detection of M. pneumoniae in 
vascular tissues. Thus, there are no other data available to compare our results with.  
In general, several factors can influence the results of PCR-based studies on detection of 
microorganisms in vascular tissues, including contamination, inhibition, size and composition 
of specimens, and the lack of standardized methods for DNA extraction and PCR assays [8].   
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We used a validated PCR assay with a high sensitivity (92 to 100%) [7]. Strict PCR 
anticontamination precautions were taken, such as the use of UDG/dUTP, to prevent carryover 
of previous PCRs. Sample processing and the PCR assay were performed in separate rooms. 
A negative control was processed with every set of five samples. To control for inhibition of 
the PCR, a second sample of each specimen was spiked with M. pneumoniae target DNA, and 
inhibited PCR samples were again purified and retested. Also, this PCR assay was used in our 
laboratory on respiratory samples. A total of 179 throat samples obtained from patients with 
respiratory tract infections were tested. These samples were sent to the laboratory for detection 
of respiratory pathogens. The M. pneumoniae PCR detected M. pneumoniae in 27 (16%) of 
the 179 samples. These results indicate that the PCR assay we used was sensitive and able to 
detect M. pneumoniae. However, it should be mentioned that there is no similarity in 
composition between vascular tissues and throat specimens.  
It has been found in a serological study that, in contrast to C. pneumoniae antibodies, M. 
pneumoniae antibodies are not associated with recurrent events in patients with unstable 
angina [6]. Using PCR, we were unable to detect M. pneumoniae in the great majority of the 
103 tested specimens. The results of this study do not support the hypothesis that M. 
pneumoniae is an important factor in the development of vascular disease. Further 
investigations are needed to confirm our results. 
 
 
Figure 1. Agarose gel 
electrophoresis of PCR 
products obtained with P1 
adhesin gene primers. (A) 
Lane M, 1-kb ladder; lanes 1 
to 5, vascular tissues of five 
patients; lane 6, negative 
control. (B) Lanes 1 to 6 
contain the same samples 
shown in panel A spiked 
with M. pneumoniae target 
DNA (positive controls).  
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Abstract  
Inter- and intralaboratory inconsistency in detection rates of Chlamydia pneumoniae in 
vascular specimens has been demonstrated. In this study, 66 vascular tissue specimens from 
66 patients with vascular disease were tested by three polymerase chain reaction (PCR) 
assays: a 16S PCR-based reverse line blot (RLB) assay, a single-step PCR, and a nested PCR. 
Also, we explored the impact of different DNA polymerase enzymes on the results based on 
gel electrophoresis and hybridization. The PCR results by gel electrophoresis in the single-
step PCR depended on which DNA polymerase was used. All samples were negative with 
Amplitaq Gold DNA polymerase, and 54.5% (36/66) were positive with the conventional Taq 
DNA polymerase. All samples were negative after hybridization with a C. pneumoniae-
specific probe. In the nested PCR all specimens were negative by gel electrophoresis and after 
hybridization. The RLB failed to detect C. pneumoniae in any specimen, however 20 
specimens were Chlamydia species (spp.)-positive. The sequence analysis of six of these 
samples demonstrated Chlamydia-like organisms. RLB detected Chlamydia spp. DNA in 
water and in the elution buffer after passage of the Qiagen columns (11/40). This study 
identified factors that may influence the detection of C. pneumoniae DNA in vascular tissues, 
and consequently biasing the link between C. pneumoniae and vascular diseases. It is strongly 
recommend to use DNA polymerases that have to be activated, to decontaminate with 
dUTP/UNG, to hybridize with specific probes, to include sufficient controls, and to use 
molecular grade water. 
 
Introduction 
The association between Chlamydia pneumoniae and vascular diseases has gained 
considerable attention in recent years. Culturing of C. pneumoniae is difficult and only in 
sporadic cases the microorganism has been successfully isolated. Therefore, molecular 
detection methods have been widely used to investigate the association between C. 
pneumoniae and vascular diseases. Several polymerase chain reaction (PCR) assays have been 
described and those described by Gaydos et al. [17], Campbell et al. [11], and Tong and Sillis 
[50] have been most widely used in various investigations. PCR assays for the detection of C. 
pneumoniae are still not standardized and investigators in the field face many problems, 
including unspecific amplification, contamination, and poor sensitivity [9, 10, 15]. 
Major inter- and intralaboratory inconsistency in detection rates of C. pneumoniae in 
vascular specimens has been demonstrated recently [3]. The same study also showed that 
many false positive results were obtained. Several issues have been linked to the variation in 
detection rate of C. pneumoniae, such as specimen collection and processing, DNA-
extraction, the choice of primers, visualization of PCR products, false positive and false 
negative signals [9].  
In this study, we investigated vascular tissue specimens, from patients undergoing surgery, 
by a 16S PCR-based reverse line blot (RLB) assay to detect C. pneumoniae DNA as well as 
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Chlamydia species (spp.) DNA. In addition, we performed the PCR assays described by 
Gaydos et al. [17] and Tong and Sillis [50]. Also we evaluated the impact of two DNA 
polymerase enzyme types on the detection of C. pneumoniae in vascular tissues. 
 
Materials and methods 
Vascular tissue specimens were obtained from 66 patients with vascular disease and 
undergoing vascular surgery. Sixty-one patients were subjected to surgery because of 
peripheral atherosclerotic disease and 5 patients because of abdominal aortic aneurysm. The 
specimens included 40 atherosclerotic specimens from the femoral artery, 9 from the carotid 
artery, 7 from the iliac artery, 5 from the popliteal artery, and 5 abdominal aortic aneurysm 
specimens. Specimens were transported to the laboratory in a Tris-EDTA buffer containing 
0.5% sodium dodecyl sulfate. In the laboratory, vascular specimens were stored at -70 0C until 
further processing. The local ethical committee approved the study and included patients gave 
their informed consent. 
 
Polymerase chain reaction 
DNA extraction from specimens was performed using the QIAamp DNA minikit (Qiagen, 
Hilden, Germany) as described previously [7]. Detection of C. pneumoniae DNA was carried 
out by the following PCR assays: assay-A1, a single-step C. pneumoniae PCR targeting the 
16S rRNA gene essentially as described by Gaydos et al. [17]. Assay-A2, as assay-A1 with 
the following modifications: uracil-DNA glycosylase (UNG) was used prior to amplification 
and dUTP was used instead of dNTP’s; AmpliTaqGold DNA polymerase was used instead of 
Taq DNA polymerase (Perkin Elmer Cetus, Norwalk, Conn.). Assay-B1, a nested C. 
pneumoniae PCR targeting the ompA gene essentially as described by Tong and Sillis [50]. 
Assay-B2, as assay-B1 but using AmpliTaqGold DNA polymerase instead of Taq DNA 
polymerase. Assay-C, an in-house Chlamydia spp. PCR targeting the 16S rRNA gene. Assay-
D, a Chlamydia spp. PCR targeting the 16S rRNA gene as described by Ossewaarde and 
Meijer [41]. Assay-D was performed only for the identification by sequencing. The primers 
and probes used in assays-A to assay-D are listed in table 1. 
To minimize the risk of contamination and to prevent carryover from previous PCR 
reactions dUTP and UNG were used in all assays except assay-A1 and the nested PCR (assay-
B1 and assay-B2). Sample processing, preparation of PCR mixtures, and PCR assays were 
performed in separate rooms. In all PCR runs of each assay positive controls in dilution series 
were included to monitor sensitivity. This was accomplished by spiking 5 known 
concentrations of C. pneumoniae DNA (strain TW-183) (range, 0.01 IFU to 100 IFU) in a 
pool of negative clinical material. In assay-C, we used a clinical sample positive for C. 
trachomatis in the COBAS Amplicor PCR assay (Roche Diagnostics Systems Inc., 
Pleasanton, Calif.) as additional control for the Chlamydia genus-, the C. pneumoniae-, and 
the C. trachomatis-specific probes.  
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Negative controls were included after every four samples during processing and PCR. 
PCR’s were performed in a PE 9600 Thermocycler (Perkin Elmer Cetus, Norwalk, Conn.) 
with the following settings:  
Assay-A1 and -A2. The PCR reaction mixture contained 30 pmol of each primer, 3 mM  
MgCl2, 200 µM of dNTP (assay-A1) or dUTP/UNG (assay-A2), 0.3 units of Taq DNA 
polymerase (assay-A1) or Amplitaq Gold DNA polymerase (assay-A2), and 5 µl extracted 
DNA. Only for assay-A2 0.25 units of UNG was used. The final reaction volume was 25 µl. 
The PCR program was as follows: 2 min at 50ºC, 10 min at 96ºC (only for assay-A2), 
followed by 40 cycles of 30s at 95ºC, 30s at 55ºC, and 1 min at 72ºC. A final step of 10 min at 
72ºC completed the PCR. 
Assays-B1 and -B2. The first PCR reaction mixture contained 10 pmol of each external 
primer, 1.5 mM MgCl2, 200 µM of dUTP, 2.5 Units of Taq DNA polymerase (assay-B1) or 
Amplitaq Gold DNA polymerase (assay-B2), and 10 µl of extracted DNA in a final volume of 
25 µl. The first PCR program consisted of 10 min at 96ºC, followed by 1 min 94ºC, 1 min 
65ºC, and 1 min 72ºC. During 22 cycles the annealing temperature was lowered 1ºC every 2 
cycles to 55ºC. Subsequently, 20 cycles were performed with 1 min at 94ºC, 1 min at 55ºC 
and 1 min at 72ºC. The second PCR mixture contained 25 pmol of each internal primer, 3 mM 
MgCl2, 200 µM of dUTP, 2.5 Units of Taq DNA polymerase (assay-B1) or Amplitaq Gold 
DNA polymerase (assay-B2), and 1 µl of the first PCR product in a final volume of 25 µl. The 
second PCR program consisted of 30 cycles of 94ºC for 1min, 50ºC for 1 min, and 72ºC for 1 
min. 
Assay-C. The PCR reaction mixture contained 20 pmol of  primer CHLF, 10 pmol of primer 
CHLR-B, 12.5 µL Hotstar-MasterMix (Qiagen, Hilden, Germany). Five micro-liter of 
template DNA was added to the mixture and the final volume was 25 µl. Samples were 
subjected to the following PCR program: two cycles of 20 sec at 95ºC, 1 min at 66ºC and 1 
min at 72ºC.  Subsequently, every two cycles the annealing temperature was lowered by 2oC 
to 56oC, followed by 40 cycles of 20 sec at 96ºC, 1 min at 56ºC and 1 min at 72ºC. The PCR 
was completed with 7 min at 72ºC.  
Assay-D: The PCR reaction contained 10 pmol of each primer, 12.5 µ of Hotstar-mastermix 
(Qiagen, Hilden, Germany). The PCR program was identical to that of assay-C described 
above. 
 
Visualization of PCR products and interpretation of results 
PCR products were visualized after electrophoresis in 2% ethidium bromide-stained agarose 
gels (MP agarose, Roche Biochemicals, Indianapolis, Ind). The PCR products (3 µl) of assay-
A and assay-B were also spotted and hybridized with the appropriate 5’-biotin-labeled probe 
(table 1). Hybridization signals were visualized using streptavidin-peroxidase and ECL 
detection reagents (Amersham, UK).  
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PCR products of assay-C were obtained with a biotinylated primer. These products were 
hybridized to the Chlamydia spp.-, C. pneumoniae- and C. trachomatis-specific 
oligonucleotide probes that were covalently bound to a Biodyne C membrane (Amersham, 
UK) using a miniblotter (Immunetics, Cambridge, Mass.) in a RLB assay (table 1 and Figure 
1). The technique of RLB hybridization has been previously described [47]. In brief; The PCR 
products were denaturated for 10 min at 99°C after dilution of 10 µl of the biotin-labeled PCR 
product in 150 µl of 2x SSPE–0.1% SDS. After denaturation, PCR products were added to the 
membrane and hybridized for 1 h at 42°C. Hybridization signals were visualized using 
streptavidin-peroxidase and ECL detection reagents (Amersham, UK). 
PCR runs were judged by negative and positive controls. The results obtained by agarose gel 
electrophoresis were scored as either PCR-positive or PCR-negative. PCR samples that gave 
clear hybridization signals in dot spot or RLB analysis were scored C. pneumoniae-positive 
and/or Chlamydia spp.-positive, according to the probe used. 
 
Statistical analysis 
Statistical analysis was performed by SPSS for windows version 11.0. A p <0.05 was 
considered statically significant. 
 
Results 
During surgery, vascular tissue specimens were obtained from 66 patients with vascular 
disease, 61 patients with peripheral atherosclerotic disease and 5 patients with abdominal 
aortic aneurysm. The mean age of patients was 61 years, range 40-89. Forty-nine patients 
(74.2%) were males and 17 (25.8%) were females.  
Samples were subjected to PCR assays A1, A2, B1, B2, and C, and the sensitivity of each 
assay was experimentally monitored in each run by a dilution series of positive controls 
spiked in negative clinical material. The lowest detection limit was 0.1 IFU for the single-step 
PCR (assay-A1 and assay-A2) and the PCR-based RLB (assay-C). The nested PCR of assay-
B1 and assay-B2 was less sensitive with 1.0 IFU as detection limit. 
The results of the PCR assays are shown in table 2. In the single-step PCR, 36 specimens 
were PCR-positive when Taq Polymerase was used (assay-A1), and none of the specimens 
was PCR-positive when AmpliTaq Gold polymerase was used (assay-A2). However, none of 
the specimens that were PCR-positive in the gel electrophoresis could be confirmed after 
hybridization with a C. pneumoniae-specific probe.  
In the nested PCR (assay-B1 and assay-B2) all specimens were PCR-negative and were also 
negative after hybridization.  
The RLB (assay-C) failed to detect C. pneumoniae in any specimen, however 20 specimens 
were Chlamydia spp-positive (Figure 1). To further specify the Chlamydia spp. found, six of 
the samples were subjected to PCR assay-D and the 16S rRNA gene fragments obtained were 
sequenced. Using the BLAST server, the sequences obtained were compared with the 
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sequences in GenBank. The sequence analysis demonstrated that these strains were 
Chlamydia Research Group 52 (one strain), Chlamydia Research Group 1 (one strain), 
Neochlamydia hartmanellae (two strains), and Endosymbiont acanthamoebae UWE (two 
strains). 
To explore the possibility that these Chlamydia-like strains were contaminants, we tested the 
water (Sigma) used in PCR mixtures, the water after passage of the Qiagen columns, and the 
elution buffer after passage of the columns. The addition of Sigma water to the PCR mixture 
of assay-C yielded no Chlamydia spp.-positive signal. Of the Qiagen column processed water 
samples, 6 out of 20 were Chlamydia spp.-positive, as well as 5 of 20 elution buffer samples. 
 
Table 1. Primers and probes used in the PCR assays 
Assay Primers Name Probes Target 
Aa TGACAACTGTAGAAATACAGC 
CGCCTCTCTCCTATAAAT 
CpnA 
CpnB 
*GACACACGTGCTACAATGGTT Cpb 16S gene 
Bc TTACAAGCCTTGCCTGTAGG 
GCGATCCCAAATGTTTAAGGC 
TTATTAATTGATGGTACAATA 
ATCTACGGCAGTAGTATAGTT 
oCP1 
oCP2 
iCPC 
iCPD 
 
 
*AGACTATGTTTTCGACCGTATCTTA 
 
 
Cp OmpA gene 
C GAGAATTTGATCTTRGTTCAG 
*CCCTTTACGCCCAATAAATCC 
CHLF 
CHLR-B 
CGTCTAGGCGGATTGAGAG 
GAATGTAGTGTAATTAGGCATCT 
AACGGAGCAATTGTTTCGA 
Csppd 16S gene 
Cp 16S gene 
Cte 16S gene 
Df CGGCGTGGATGAGGCAT 
TCAGTCCCAGTGTTGGC 
16SIGF 
16SIGR 
 Cspp 16S gene 
*5’-Biotinylated. a, c, fReferences 17, 50 and 41, respectively. bCp, C. pneumoniae. dCspp, 
Chlamydia species. eCt, C. trachomatis.  
 
Table 2. PCR results in 66 vascular specimens by different PCR assays 
        Single-step PCR          Nested PCR PCR-based RLB a 
No. of specimens Assay-A1b Assay-A2b Assay-B1b Assay-B2 b      Assay-Cb 
18 - c - - -        - 
28 PCR+d - - -        - 
  8 PCR+ - - -        Cspp+ e 
12 - - - -        Cspp+ 
Total  (n=66) f 36 0 0 0        20 
aRLB, reverse line blot. bIn assay-A1 and assay-B1, Taq Polymerase was used; in assay-A2 and 
assay-B2, AmpliTaq Gold polymerase was used; in assay-C, HotStarTaq DNA polymerase was used. 
c-, PCR was negative both in agarose gel electrophoresis and after hybridization. dPCR+, PCR was 
positive in agarose gel electrophoresis and negative after hybridization. eCspp+, Chlamydia species-
positive in RLB hybridization. fNone of the specimens was C. pneumoniae-positive. 
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Discussion 
The possible role of C. pneumoniae in the pathogenesis of vascular disease has been widely 
investigated. The DNA amplification of C. pneumoniae specific sequences in vascular tissue 
specimens however, has been shown to vary greatly between study groups. More recent 
reports have criticized the lack of standardization of C. pneumoniae PCR methodology [3, 4, 
15]. 
In this study we investigated vascular tissue specimens of 66 patients by the PCR assays that 
have been most widely used [17, 50], and we explored the impact of different DNA 
polymerase enzymes on the results based on agarose gel electrophoresis and after 
hybridization. In addition, we investigated the presence of Chlamydia spp. DNA in the 66 
samples, using a Chlamydia spp. PCR and RLB hybridization with both a Chlamydia spp.-
specific and a C. pneumoniae-specific probe. 
The rate of PCR-positive signals by gel electrophoresis in the single-step PCR depended on 
which DNA polymerase was used. When the conventional Taq DNA polymerase was used 
(assay-A1), 36 specimens (54.5%) were PCR-positive. If agarose gel electrophoresis had been 
the final method of detection in combination with the use of Taq DNA polymerase, 36 of 66 
samples would have been labeled C. pneumoniae-positive in our study. These 36 samples 
however could not be confirmed by hybridization of the PCR products with a C. pneumoniae-
specific probe. Also these samples were negative when Amplitaq Gold DNA polymerase was 
used. This may be due to the production of more specific products by Amplitaq Gold DNA 
polymerase than the conventional Taq DNA polymerase. DNA polymerase enzymes like 
Amplitaq Gold or Hotstart that need to be activated at elevated temperature are known to 
enhance the specificity of a PCR assay [27]. Reviewing the literature on the use of Amplitaq 
Gold DNA polymerase in C. pneumoniae PCR assays we found that in the majority of the 
studies, it was not mentioned which type of DNA polymerase enzyme was used. In a study 
that explicitly mentioned the use of Amplitaq Gold DNA polymerase, the detection rate of C. 
pneumoniae DNA was 14.8% [30].  
 
 
 
 
 
Chlamydia spp._____ 
Chlamydia spp._____  
C. pneumoniae_____ 
C. pneumoniae_____ 
C. trachomatis_____ 
C. trachomatis_____ 
     1     2     3      4      5      6     7      8     9     10 
Figure 1. Part of the reversed line blot after hybridization with PCR products obtained from controls and 
clinical specimens. 200pmol and 100 pmol of Chlamydia genus-, pneumoniae-, and trachomatis-specific 
probes were spotted horizontally as indicated on the left. PCR products were hybridized vertically. Lane 1, 10 
IFUs C. pneumoniae DNA; lane 2, 1.0 IFU C. pneumoniae DNA; lanes 3 and 7, negative controls; lanes 4-6 
and 8-10, clinical specimens. 
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Hybridization is also an important measure to minimize false PCR-positive signals, and the 
advantages of confirmation of PCR-positive signals by hybridization with a specific probe 
have been described before [4]. Analyzing 33 studies with regard to hybridization in the 
detection of C. pneumoniae DNA, we found 11 studies in which only gel electrophoresis had 
been used to visualize PCR products [8, 16, 18, 30, 37, 38, 40, 42-45]. In the other 22 studies, 
PCR results were confirmed by hybridization [2, 5, 6, 12, 14, 19, 23-26, 28, 29, 31-35, 39, 46, 
48, 49, 51]. The detection rate was significantly higher in studies with only gel electrophoresis 
than in studies with hybridization, 31.6% (204/645) and 24.5% (367/1492), respectively 
(P=0.0009). It is possible that the results of studies without hybridization are confounded by 
unspecific PCR-positive signals that are, incorrectly, interpreted C. pneumoniae-positive. 
Using the Chlamydia spp. PCR and RLB hybridization we detected Chlamydia spp. DNA in 
30% (20/66) of the specimens. Identification by sequence analysis of 6 of 20 PCR positive 
samples demonstrated the presence of Chlamydia-like organisms, including Endosymbiont 
acanthamoebae and Neochlamydia hartmanellae.  
Chlamydia-like organisms may infect free-living amoebae that are common inhabitants of 
the aquatic environment. Amoebae may act as reservoir for these organisms, implying that 
Chlamydia-like organisms have potential for widespread dissemination [20]. They have been 
detected in nasal mucosa of healthy persons, in broncho-alveolar lavage of patients with 
respiratory tract infection, and in abdominal aneurysms [1, 13, 22, 41]. It has been 
demonstrated that elementary and reticulate bodies of Chlamydia-like organisms behave, in 
the life cycle, similarly to the chlamydial elementary and reticulate bodies [21]. In addition, 
the 16S rRNA sequence analysis of eight Chlamydia-like strains has been shown to be highly 
homologous with C. pneumoniae, varying from 85% to 87.6% [20]. The potential pathogenic 
role of Chlamydia-like organisms has not been established, and there is no evidence that 
Chlamydia-like organisms are associated with vascular diseases. Furthermore, it is possible 
that these strains were not originally present in the patients’ specimens, and the positive PCR 
signals found might be a result of contamination with the environmental Chlamydia-like 
organisms [36, 41]. 
Indeed, we demonstrated the presence of Chlamydia spp. DNA by RLB in 11 samples after 
passage of the Qiagen columns, including elution buffer and distilled water. In the light of the 
homology between Chlamydia-like organisms and C. pneumoniae, one might hypothesize that 
sequence homology with Chlamydia-like organisms might be responsible for positive results 
in C. pneumoniae PCR assays. This may, in part, explain the inter- and intralaboratory 
discrepancy in the detection of C. pneumoniae in vascular tissue specimens.  
In the nested PCR, all specimens were negative both by gel electrophoresis and by 
hybridization. Since the nested PCR was based on the sequence of the OmpA gene, a gene 
that usually shows more sequence variation compared to the 16S rRNA gene, no effect of the 
DNA polymerase was found in this assay. The disadvantage of the nested PCR is that no anti-
contamination with dUTP/UNG can be used. Therefore it is most sensitive to contamination. 
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This study identified important factors that may have contributed to bias and once more 
shows the important influence of methodological factors on the detection of C. pneumoniae 
DNA in vascular tissues. In conclusion, we strongly recommend the use of DNA polymerases 
that have to be activated, the use of dUTP/UNG anti contamination, hybridization with 
specific probes, the inclusion of sufficient controls, the use of molecular grade water, and 
cautious interpretation of the results when column-based DNA extraction methods like 
Qiagen are used. This study furthermore stresses the biases that unstandardized methodology 
may introduce in the context of the possible link between C. pneumoniae and vascular 
diseases. 
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Abstract 
Several, small clinical trials have indicated that antibiotic treatment of Chlamydia pneumoniae 
is associated with a better outcome in patients with coronary artery disease  (CAD). It has not 
been demonstrated if antibiotic treatment eradicates C. pneumoniae from vascular tissue. The 
aim of this study was to assess the effect of clarithromycin on the presence of C. pneumoniae 
in vascular tissue of patients with CAD. Patients with CAD, waiting for coronary artery 
bypass graft surgery were enrolled into a randomized, double-blind, placebo-controlled trial. 
Patients were treated with clarithromycin 500 mg or placebo once daily, from the day of 
inclusion until surgery. During surgery several vascular specimens were obtained. The 
presence of C. pneumoniae in vascular specimens was examined by immunohistochemistry 
(IHC) and two polymerase chain reaction (PCR) assays. Chlamydia IgG titers were 
determined using an enzyme immunoassay, at inclusion and 8 weeks after surgery. A total of 
76 patients were included and 180 vascular specimens were obtained (80 specimens from the 
clarithromycin group and 100 specimens from the placebo group). 35 patients received 
clarithromycin (mean duration 27 days, SD 12.2 ) and 41 placebo (mean duration 27 days, SD 
13.9). IHC detected C. pneumoniae major outer membrane protein antigen in 73.8% of 
specimens in the clarithromycin group vs. 77.0% in the placebo group (p = ns). Chlamydia 
lipopolysaccharide antigen was found in one placebo specimen only. C. pneumoniae DNA 
was not detected in any specimen. Baseline Chlamydia IgG titers were equally distributed in 
both groups and were not significantly different after treatment. There is no indication of the 
presence of viable organisms in vascular tissue. Clarithromycin treatment of patients with 
CAD has no effect on the presence of C. pneumoniae in vascular tissue or on Chlamydia IgG 
titers. 
 
Introduction 
Many risk factors for atherosclerosis have been identified. However, atherogenesis is not fully 
understood and recently infectious pathogens, particularly Chlamydia pneumoniae, have been 
considered as potential risk factors for atherosclerosis [1]. It has been proposed that, during 
respiratory tract infection, C. pneumoniae reaches vascular tissue via infected leukocytes. In 
vascular tissue, C. pneumoniae can infect atheroma-associated cells and induce inflammatory 
cytokines production and smooth muscle cells proliferation [2]. C. pneumoniae may also 
cause endothelial dysfunction and promote the secretion of matrix-degrading 
metalloproteinases that destabilize the atherosclerotic plaque [2, 3]. Chlamydial 
lipopolysaccharide (LPS) and chlamydial heat shock protein 60 kd may contribute to 
atherogenesis by promoting foam cells formation, lipoprotein oxidation and proinflammatory 
activation [2]. 
Some seroepidemiologic studies have found an association between C. pneumoniae and 
coronary artery disease (CAD). Prospective serologic studies, however, failed to demonstrate 
any association [4]. Further indications that C. pneumoniae might play a role in atherogenesis 
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came from studies that identified C. pneumoniae in vascular tissue by polymerase chain 
reaction (PCR), immunohistochemical staining (IHC), electron microscopy, and culture [1]. 
However, the results of these studies are inconsistent and huge variations in detection rates are 
reported [1, 5]. 
The results of some small clinical trials that showed beneficial effects from antibiotic 
treatment encouraged many groups to further investigate the effect of antibiotic treatment on 
secondary prevention of cardiovascular events [6-8]. These studies are based on the 
hypothesis that antibiotic treatment of C. pneumoniae eradicates the organism from the 
vascular wall in CAD patients. This will end the infectious process, which will stabilize 
atheromas and decrease cardiovascular events. However, it has not been studied whether 
antibiotic treatment eradicates C. pneumoniae from vascular tissue of CAD patients. We 
initiated a placebo-controlled, double-blind, randomized clinical trial to investigate the effect 
of clarithromycin treatment on the presence of C. pneumoniae in vascular tissue, and on 
circulating Chlamydia IgG antibodies in patients with CAD.  
 
Patients, materials and methods 
Study population 
Between July 1999 and July 2001, patients with documented CAD and scheduled for coronary 
artery bypass graft (CABG) surgery were invited to participate in the study. Inclusion was 
carried out during attendance at the pre-operative outpatient clinic at the department of 
thoracic surgery of the Amphia Hospital. Exclusion criteria included: (I) concomitant 
administration of terfenadine, rifabutin or cisapride; (II) antibiotic therapy with a macrolide, 
tetracycline, or quinolone within three months prior to inclusion or during the study period; 
(III) renal failure (serum creatinine rates above 150 µmol/l); (IV) elevated liver function tests 
(alanine-aminotransferase > 55 U/l, aspartate-aminotransferase > 45 U/l, total bilirubin > 27 
µmol/l, or alkaline phosphatase  > 180 U/l); (V) female patients capable of child-bearing but 
not taking adequate birth control precautions.  
After giving informed consent, patients were randomized in a double-blind, placebo 
controlled trial. Patients received, from the day of inclusion until the day of surgery, a daily 
dose of clarithromycin 500 mg slow release (SR) or a placebo tablet (Clarithromycin SR and 
matching placebo tablets were obtained from Abbott laboratories, Abbott Laboratories Ltd, 
Queenborough, Kent, England ME11 5EL).   
An independent pharmacist dispensed either clarithromycin or placebo tablets according to a 
computer-generated randomization table, which stratified in groups of 10. The researcher 
responsible for seeing the patients allocated the next available number on entry into the trial, 
and provided the patient the corresponding tablets. The code was revealed to the researcher 
once recruitment, data collection, and laboratory analysis were complete. The local Medical 
Ethics Committee approved the study. 
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Clinical specimens 
During CABG surgery specimens were obtained from coronary atheromas, obstructed old 
coronary grafts, mammary artery, and saphenal vein, when possible. All specimens were 
divided into two portions, one for IHC and one for PCR. IHC samples were routinely fixed in 
10% buffered formalin until further research. PCR samples were transported at 4 ºC in 200 µl 
of lysis buffer (1M Tris pH 7.0, 0.5 mM EDTA, 5M NaCl, 1% SDS, 20 mg/ml proteinase K), 
and processed within 24 hours. 
From each patient 10 ml blood was obtained on the day of inclusion and 8 weeks after 
surgery. Blood was stored at 4 °C immediately after collection, and centrifuged within two 
hours. Serum was then stored at − 20 °C pending further testing. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Trial profile. 
 
 
Laboratory methods 
Serology 
Chlamydia IgG antibody titers were determined by a recombinant enzyme immunoassay 
(rELISA, Medac GmbH, Hamburg, Germany) according to the manufacturer’s instructions. 
This rELISA uses a recombinant Chlamydia-specific LPS fragment as antigen. An IgG titer of 
> 1:100 was considered positive.   
 
Immunohistochemistry 
Cross-sections of each paraffin wax embedded vascular specimen were stained with 
hematoxilin-eosin stain. In each cross-section, the lumen area, the circumference of the 
internal elastic lamina and the area encompassed by it, were evaluated. Antigens were 
80 total eligible patients 
80 patients randomized 
38 clarithromycin 
3 excluded from analysis 
because of concomitant 
use of other antibiotics 
during study period 
1 excluded from analysis 
because of concomitant 
use of other antibiotics 
during study period 
       42 placebo 
35 analyzed 41 analyzed 
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detected in 4 µm sections by IHC as described by Meijer et al. [9]. In the IHC, two 
monoclonal antibodies were used. The species specific monoclonal antibody RR-402 against 
C. pneumoniae major outer membrane protein (MOMP) (Washington Research Foundation, 
Seattle, Washington, USA) [10], and the Chlamydia genus specific anti-LPS monoclonal 
antibody 16.3B6 (produced by the National Institute of Public Health and the Environment, 
Bilthoven, The Netherlands). HEp2 cells (CCL23; American Type Culture Collection) 
infected with C. pneumoniae strain TW-183 were used as positive control, and mock-infected 
HEp2 cells were used as negative control.  
The specimens were evaluated microscopically by one experienced technician. Specimens 
were considered positive for C. pneumoniae antigen when a clear dot-like-cell associated 
staining was observed [5].  
 
Polymerase chain reaction 
Specimens processing 
Within 24 hours after surgery, DNA was extracted from clinical specimens by the QIAamp 
DNA mini kit (Qiagen Inc., Valencia, Calif.) according to the manufacturer’s instructions. A 
control was included with every four clinical specimens in the extraction procedure. 
 
Real-time PCR 
A real-time PCR assay specific for C. pneumoniae and designed to the VD4 variable domain 
of the ompA gene was performed. Oligonucleotide primers included VD4 forward primer (5'-
TCC GCA TTG CTC AGC C-3'), VD4 reversed primer (5'-AAA CAA TTT GCA TGA AGT 
CTG AGA A-3'), and a VD4 probe (5'-FAM-TAA ACT TAA CTG CAT GGA ACC CTT 
CTT TAC TAG G-TAMRA) [11]. 
To be able to monitor possible inhibition of PCR in the clinical specimens a universal 
internal control was used. This internal control sample consisted of a whole-virus preparation 
of phocid herpesvirus (PhHV-1) [12], which was added to the original clinical sample at a 
final concentration of approximately 5,000 to 10,000 DNA copies per ml. Primers PhHV-F1 
(5'-GGG CGA ATC ACA GAT TGA ATC-3'), PhHV-R1 (5'-GCG GTT CCA AAC GTA 
CCA A-3') and probe (5'-VIC-TTT TTT ATG TGT CCG CCA CCA TCT GGA TC-
TAMRA-3') were used to amplify PhHV1, which in uninhibited samples had a cycle threshold 
value of approximately 30. Amplification was carried out with both C. pneumoniae and 
PhHV1 specific primers and probes in a multiplex PCR. 
Reactions were prepared with 96-well MicroAmp optical plate (Applied Biosystems) by 
addition of 5 µl of extracted DNA to 45 µl of PCR mixture containing 1x TaqMan universal 
PCR master mix (Applied Biosystems), 600nM VD4 forward primer, 300nM VD4 reversed 
primer, and 150 nM FAM fluorescent C. pneumoniae specific probe, 5 µl PhHV1 (whole-
virus), 400 nM PhHV-F1 forward primer, 400 nM PhHV-R1 reversed primer, and 150 nM 
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VIC-labeled PhHV-1 specific probe. The 96-well plate was centrifuged for 1 min at 1,000 xg 
at room temperature in a swing-out rotor to remove small air bubbles in the reaction vessels.   
Amplification and detection were performed with an ABI Prism 7900HT sequence detection 
system (Applied Biosystems) by using the manufacturer's standard protocols. The PCR 
cycling program consisted of 2 min at 50°C, 10 min at 95°C, and 50 cycles of 15s at 95°C and 
1 min at 60°C. Each run contained: (I) negative controls (one for every four extracted DNA 
samples); (II) positive control series containing a known amount of inclusion forming units 
(IFU) of C. pneumoniae (5, 2, and 1 IFU); (III) a negative mix control. A specimen was 
considered positive for C. pneumoniae if the fluorescence was above the threshold limit. 
Specimens were considered negative for C. pneumoniae if the internal control was positive 
with a cycle threshold value of < 35. 
 
Industry-developed research-use-only LCx C. pneumoniae PCR (RUO-PCR) 
The presence of C. pneumoniae DNA in specimens was also examined by an Industry-
developed LCx C. pneumoniae RUO-PCR (Diagnostics Division, Abbott Laboratories, 
Abbott Park, Chicago, Illinois, USA). The RUO-PCR assay was performed at Abbott 
Laboratories by Abbott personnel as described earlier [13]. Briefly, an activation mixture was 
prepared by mixing equal volumes of LCx Activation Reagent II and LCx C. pneumoniae 
Oligo Mix. 40 µl of the freshly prepared activation mixture and 30 µl of the purified DNA 
samples were subsequently added to the appropriate LCx amplification vial. The total reaction 
volume was 200 µl. Amplification was carried out with a 480 thermocycler (Perkin-Elmer, 
Norwalk, Conn.) under the following conditions: 97°C for 2 min; 40 cycles of 97°C for 30 s, 
59°C for 30 s, and 72°C for 30 s; and finally, 1 cycle of 97°C for 5 min and 12°C for 5 min. 
PCR products were detected with the LCx Analyzer. Samples yielding a rate over 100 cps per 
second were considered C. pneumoniae positive. This cutoff was determined by testing 
titerated C. pneumoniae isolates and uninfected HEp-2 cell DNA multiple times [13].  
Specimens were coded and all detection experiments were performed blind. The code was 
revealed when the study was completed. 
 
Statistical analysis 
All baseline characteristics were analyzed using a χ2-test or a Student’s t test when 
appropriate. A value of P<0·05 was considered statistically significant. The SPSS 11·0 
statistical software package was used for all calculations. 
 
Role of the funding source 
Abbott Pharmaceuticals supported this study with an unrestricted educational grant. Also, 
RUO-PCR was performed by Abbott Laboratories. The sponsor played no role in study 
design, data analysis, data interpretation, writing of the report, or in the decision to submit the 
report for publication. 
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Results 
Figure 1 shows that a total of 80 patients with CAD, waiting for CABG surgery, were enrolled 
in the study. Four patients who during the study period concomitantly used other antibiotics 
were excluded from this treatment analysis due to possible additive effects. Thirty-five 
patients were randomly assigned to receive clarithromycin and 41 to receive placebo. Table 1 
shows that the baseline patient characteristics are well balanced between the two treatment 
groups. The mean number of treatment-days, for both groups, was 27 as indicated by the 
number of tablets used.  
 
Table 1. Baseline patient characteristicsa 
Characteristics Clarithromycin, 
N = 35 
Placebo, 
N = 41 
   Male  32 (91.4)  35 (85.3) 
   Age, mean  65 (8.6)  65 (9.3) 
   Weight, mean  84 (19.4)  81 (12.1) 
   Length, mean 170 (20.2) 174 (9.9) 
   NYHA-score, mean   3 (0.9)   3 (0.7) 
   Treatment-days, mean  27 (12.2)  27 (13.9) 
   Current smoker   5 (14.3%)   4 (9.8%) 
   Smoker in past 27 (77.1)  31 (75.6) 
Medical history   
   COPD   6 (17.1)   3 (7.3) 
  2 (5.7)   1 (2.4)    Diabetes Mellitus   - Type I 
                                 - Type II   4 (11.4)   8 (19.5) 
   Hypercholesterolaemia 20 (57.1)  27 (65.9) 
   Malignancy   3 (8.6)   1 (2.4) 
   CVA or TIA   2 (5.7)   6 (14.6) 
   Pectoral angina  33 (94.3)  40 (97.6) 
   Myocardial infarction  20 (57.1)  23 (56.1) 
   Valvular insufficiency   3 (8.6)    1 (2.4) 
   Hypertension  18 (51.4)  25 (61.0) 
   Earlier vascular surgery  10 (28.6)  15 (36.6) 
Family medical history   
   Cardiovascular disease  29 (82.9)  31 (75.6) 
   Diabetes mellitus   7 (20.0)   6 (14.6) 
Medication   
   Statins  21 (60.0)  27 (65.9) 
   Anti-hypertensive drugs  35 (100)  41 (100) 
Values are means (SD) or numbers (%); aBaseline patient characteristics are not significantly different 
between the treatment groups. 
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During CABG surgery, 180 vascular specimens were obtained, including coronary 
atheromas (n = 31), obstructed old CABG specimens (n=12), mammary artery specimens (n = 
66), and saphenal vein specimens (n = 71). All atheromas and obstructed old CABG 
specimens showed histological signs of inflammation and advanced atherosclerosis (thickened 
intima, plaques with thrombus, lymfocytes, foamcells, surface defects). The other specimens 
showed normal to slightly thickened vascular walls.  
The results of IHC are presented in table 2. C. pneumoniae MOMP antigen was found in the 
majority of specimens of both study groups. Chlamydia LPS antigen was found only once, in 
an atheroma from the placebo group. There was no significant difference in the presence of 
antigens between the two groups. The real-time PCR and the RUO-PCR failed to detect C. 
pneumoniae DNA in the 180 vascular specimens. 
Chlamydia IgG antibody titers were measured on inclusion (baseline serology) and 8 weeks 
after completion of treatment. Baseline serology was positive in 81.6% and 73.8% of the 
patients in the clarithromycin group and the placebo group, respectively. The corresponding 
percentages 8 weeks after treatment were 78.9% and 66.7%, respectively. Clarithromycin had 
no significant effect on Chlamydia IgG antibody titers. In both treatment groups, Chlamydia 
IgG antibody titers after treatment were not significantly different compared with the baseline 
titers. 
 
Table 2. Results of immunohistochemical staining of the vascular specimens from the study patientsa 
 Clarithromycin Placebo P value b 
 Positive specimens/ 
specimens tested, (%) 
Positive specimens/ 
specimens tested, (%) 
 
Coronary atheroma    
                  MOMPc 10/14 (71.4) 10/17 (58.8) 0.47 
                  LPSd  0/14 (0)  1/17 (5.9) 0.36 
Old coronary grafte    
                  MOMP  6/6 (100)  5/6 (83.3) 0.30 
                  LPS  0/6 (0)  0/6 (0) 1.0 
Mammary artery    
                  MOMP 22/28 (78.6) 30/38 (78.9) 0.97 
                  LPS  0/28 (0)  0/38 (0) 1.0 
Saphenal vein    
                  MOMP 21/32 (65.6) 32/39 (82.1) 0.11 
                  LPS  0/32 (0)  0/39 (0) 1.0 
Total     
                  MOMP 59/80 (73.7) 77/100 (77.0) 0.69 
                  LPS 0/80 (0)  1/100 (1.0) 1.0 
Values are numbers (%); amore than one specimen was obtained from some patients; ba p-value of < 
0,05 is considered statistically significant; cMOMP, C. pneumoniae major outer membrane protein 
antigen; dLPS, Chlamydia lipopolysaccharide antigen; e Obstructed old bypass graft from earlier 
CABG procedure. 
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Discussion 
Macrolide antibiotics, including clarithromycin, are active against C. pneumoniae. The 
hypothesis that C. pneumoniae is a risk factor for atherosclerosis has lead to clinical trials of 
macrolide treatment in patients with CAD [8]. Human placebo-controlled trials have been 
performed to investigate the clinical effects of antibiotics in patients with vascular disease. 
These studies follow the hypothesis that macrolides will kill C. pneumoniae in the vascular 
wall, which will subsequently end the infectious process. Thereby, the plaque will be 
stabilized which will result in fewer complications of atherosclerosis. However, whether 
antibiotic treatment has an effect on the presence of the microorganism in vascular tissue has 
not been studied well.  
In the present study, vascular specimens were tested by an automated real-time PCR, which 
combines amplification, hybridization and quantitative product detection. Also, the specimens 
were tested by an industry-developed RUO-PCR. Both methods failed to detect C. 
pneumoniae DNA in any specimen. This indicates that there is no evidence of active C. 
pneumoniae infection in vascular tissue of CAD patients. This questions the use of antibiotics 
for this indication. Possible explanations for the negative results of the PCR assays could be 
the low DNA concentration in the test samples and the patchy distribution of C. pneumoniae 
DNA in vascular tissue [14]. 
Melissano et al. [15] evaluated the effect of roxithromycin on C. pneumoniae in carotid 
atheromas. The authors concluded that roxithromycin treatment was effective in eradicating 
C. pneumoniae from carotid atheromas since C. pneumoniae DNA was detected in 31% 
(5/16) of the atheromas in the roxithromycin group and in 75% (12/16) of the atheromas in the 
control group. However, they used a conventional semi-nested PCR assay to detect C. 
pneumoniae DNA. Conventional PCR assays are unstandardized and known to produce 
conflicting results, including false-positives [16, 17]. Also, this small trial was unblinded 
which limits the accuracy of their results. Efforts have been recently focussed on the 
establishment of quantitative real-time PCR and on RUO-PCR technology. The first reports 
on the evaluation of these tests suggest that they are sensitive, specific and reproducible [13, 
18]. The conclusion from our DNA-detection experiments must be that there is no active C. 
pneumoniae infection in vascular tissue of patients with CAD. 
The results from IHC were different. A high prevalence of C. pneumoniae MOMP antigen 
was found in both groups. Chlamydia LPS antigen was detected by IHC in only one specimen 
from the placebo group. These results are consistent with the findings of other investigators. 
The abundance of MOMP antigen and low detection rate of LPS antigen in vascular 
specimens has been reported before [1, 9, 22]. IHC is a valuable technique, which is limited 
by a subjective reading and interpretation. This remains difficult because of background 
staining and nonspecific staining with antigenic components in vascular specimens, such as 
inflammatory cells and tissue components [19-21]. It is also possible that components of 
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Chlamydia-like microorganisms described recently can cause cross-reactivity to the 
monoclonal antibodies used in IHC staining [9]. 
The conflicting results concerning the high detection rate of C. pneumoniae MOMP antigen 
and the low detection rate of C. pneumoniae DNA might be partly explained by the biology of 
chlamydiae [23]. Alternation of activity and latency characterizes infections with chlamydiae. 
In advanced chlamydiae infections, the pathogen is no longer present, whereas its antigens can 
persist for a long time. The persisting antigens may cause a cascade of events leading to 
fibrosis and scarring [23]. This proposed pathophysiology is in line with our findings. 
In the present study, we could not demonstrate any effect of clarithromycin on the presence 
of C. pneumoniae MOMP antigen in vascular tissue. Similar finding has been demonstrated in 
animal models. Antibiotic treatment with azithromycin was not associated with elimination of 
chlamydial antigen from vascular specimens of rabbits infected with C. pneumoniae [24]. 
Also, in a mice model, azithromycin treatment did not affect the presence of C. pneumoniae in 
the aorta, lung, or spleen [25]. 
Clarithromycin treatment had no effect on Chlamydia IgG antibody titers, and we found no 
significant difference between baseline titers and the titers measured 8 weeks after treatment. 
Circulating Chlamydia antibody titers have been used as a marker of response to antibiotic 
treatment. Gupta et al. [6] reported a significant effect of azithromycin on Chlamydia IgG 
antibody titers. However, our study supports the results of other trials that have found that 
antibiotic therapy does not influence Chlamydia antibody titers in patients with vascular 
disease [26-30]. 
This is the first placebo-controlled, double-blind, randomized clinical trial that assessed the 
effect of antibiotic treatment on the presence of C. pneumoniae in vascular tissue. The major 
finding in this study is, that in vascular tissue, including atherosclerotic plaques of patients 
with advanced CAD, no viable C. pneumoniae are present. Only MOMP-antigen was found. 
Since viable C. pneumoniae are no longer present in vascular tissue, it is most unlikely that 
antibiotic treatment will have any effect in patients with advanced atherosclerosis. This 
explains the results of many clinical trials that failed to demonstrate any beneficial effect of 
antibiotic treatment in patients with vascular disease [26-32]. 
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A link between infectious agents and vascular diseases has been proposed for decades. Since 
the well-defined risk factors for vascular diseases cannot explain all cases, attention has been 
recently focused on investigating hypothetical additional risk factors (chapter 1). The theory 
that inflammation contributes to the pathogenesis of vascular diseases has gained more 
support over the past few years. An association between elevated markers of systemic 
inflammation and vascular disease has been demonstrated [18]. However, several factors 
might be responsible for inflammation found in patients with vascular disease [12]. 
Microorganisms, especially Chlamydia pneumoniae, have been postulated as potential risk 
factors for vascular diseases. The first report of a possible association between C. pneumoniae 
and vascular disease came from a Finish group in 1988 [80]. Since then, a huge number of 
reports addressing the involvement of C. pneumoniae in the pathogenesis of vascular diseases 
has been published. These reports include seroepidemiologic studies, pathologic and 
molecular studies, animal model studies, and clinical antibiotic treatment trials. The data in 
these studies were obtained by microimmunofluorescence test (MIF), enzyme immunoassays 
(ELISA), polymerase chain reaction (PCR), immunohistochemistry (IHC), and sporadically 
by electron microscopy and culture. The studies presented in this thesis were performed to 
further investigate the possible link between C. pneumoniae and vascular diseases. 
The association between C. pneumoniae and vascular diseases was initially based on 
serology. Three meta-analysis reports addressed this association. Eighteen early 
seroepidemiologic studies were analyzed by Danesh et al. [17]. Only one study failed to detect 
an association between vascular diseases and seropositivity to C. pneumoniae. The other 17 
studies found odds ratios for association ranging from 1.2 to more than 8. However, only three 
of these studies were prospective. Three years later, Danesh et al. [19] analyzed 15 
seroepidemiologic prospective studies. This analysis showed a weak association to no 
association at all, and the combined odds ratio of 15 studies for IgG was 1.5 (95% CI, 0.97-
1.36). These findings were confirmed by a third meta-analysis that included 38 studies [10]. 
The cross-sectional studies demonstrated an association between C. pneumoniae 
seropositivity and vascular diseases, whereas in prospective studies no association was found 
[10]. 
In this thesis, the seroepidemiologic link between C. pneumoniae and vascular diseases was 
assessed by two case-control studies (chapters 3, 4, and 5). In a case-control study of patients 
with abdominal aortic aneurysm (AAA), we found inconsistent serologic results concerning 
the association between C. pneumoniae and AAA (chapter 3 and 4). We observed that 
serologic methods have an important implication on the serologic association between C. 
pneumoniae and AAA. Serology was performed by five different tests: two MIF tests (MRL-
MIF and Savyon-MIF) and three ELISA’s (Medac-rELISA, Savyon-ELISA and Bioclone-
ELISA). Only in the MRL-MIF test, a significant association was found (odds ratio 6.8, 95% 
CI, 2.0-24). The other four tests showed no association. However, when the higher IgG titers 
were used as cutoff, also the MRL-MIF test failed to demonstrate any association between C. 
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pneumoniae and AAA. The link between low IgG titers of C. pneumoniae and AAA, 
demonstrated by the MRL-MIF test, might be a result of cross-reaction between the antigen 
used in the test and non-chlamydial components related to AAA, such as inflammatory cells 
and tissue components. Furthermore, the agreement between the five different tests was poor. 
In order to investigate the hypothesis that C. pneumoniae might be responsible for 
inflammation associated with venous thrombosis, we evaluated C. pneumoniae seropositivity 
in a case-control study of patients with venous thrombosis (chapter 5). The results showed no 
association between C. pneumoniae and an increased risk for venous thrombosis. IgG 
antibody titers against C. pneumoniae, measured by a MIF test, were not correlated with the 
concentrations of the inflammatory mediators IL-6 and IL-8. This indicates that the 
inflammatory process shown in patients with venous thrombosis is not related to C. 
pneumoniae infection. Venous thrombosis is a multicausal disease and several genetic and 
acquired risk factors have been identified [79]. However, about one-third of episodes of 
venous thrombosis cannot be explained by the established risk factors. It has been suggested 
that inflammatory processes are involved in the pathogenesis of venous thrombosis [87]. 
However, the mechanism by which inflammation could be involved in this disease remains 
unknown. Our results do not support the hypothesis that C. pneumoniae infection is a risk 
factor for venous thrombosis. The link between C. pneumoniae and venous thrombosis was 
addressed in three other seroepidemiologic reports. These reports produced conflicting results. 
Two reports suggested that C. pneumoniae is associated with venous thrombosis [22, 52], 
whereas the third report did not confirm such an association [46].  
Our serologic findings (chapters 3, 4, and 5) are consistent with the results of other studies. 
A multi-center study demonstrated interlaboratory inconsistency in C. pneumoniae serology 
measured by the MIF test [74]. Twenty-two identical sera were tested in 14 laboratories from 
8 countries. The agreement with the reference laboratory ranged from 60% to 90%. A poor 
agreement between serologic tests for C. pneumoniae was also demonstrated in two recent 
studies evaluating the agreement between serologic tests in patients with vascular disease [32, 
83]. Several factors may contribute to disagreement between C. pneumoniae serologic tests 
including the subjective interpretation, the test procedure, the type of the antigen used, its 
purity and its concentration [30]. Serologic tests for C. pneumoniae are not standardized. 
Commercial and in-house made serologic assays have not been adequately evaluated in 
patients with infection documented by culture [29]. In these assays different antigens are used, 
including purified elementary bodies (lipopolysaccharide (LPS)-extracted), purified major 
outer membrane protein (MOMP), and recombinant LPS-fragment. In addition, the definition 
of acute, chronic and past infection is based on different cutoffs and different criteria, 
depending on the serologic assays that are used. There is accumulating evidence that C. 
pneumoniae serologic tests are less specific than assumed. Unspecific reactivity in serologic 
tests, including cross-reactivity between C. pneumoniae and other Chlamydia species, has 
been demonstrated [30, 45, 63]. This probably is due to a lack of LPS removal from the 
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elementary bodies during antigen preparation. Unspecific serologic reaction may result from 
cross-reaction with the MOMP of different Chlamydia species or from cross-reaction with 
LPS [14, 73]. There have been also reports on a possible cross-reactivity to Bordetella 
pertusis and parvovirus [39, 59, 75]. The recently described new Chlamydia-like species 
belonging to three new families (Parachlamydiaceae, Waddliaceae and Simkaniaceae) in the 
order Chlamydiales may also cause serologic antigenic cross-reactivity with C. pneumoniae, 
since there is evidence that these strains display molecular cross-reactivity with C. 
pneumoniae [32, 71]. 
We observed a high seroprevalence of C. pneumoniae antibodies in healthy controls and in 
patients with AAA, venous thrombosis, and cardiovascular disease (chapters 3, 4, 5, 6, and 9). 
This is consistent with the findings of many seroepidemiologic studies that measured high 
seropositivity in patients with vascular diseases and in the general population [25, 32, 45]. We 
consistently defined positive serology as a marker of exposure to C. pneumoniae. However, 
seropositivity to C. pneumoniae has been interpreted in several ways and the definition of 
acute, chronic and persistent infection varied among reports [29]. The serologic criteria of C. 
pneumoniae infection are not standardized [12]. The Centers of Disease Control and 
Prevention (USA) and the Laboratory Centre for Disease Control (Canada) have 
recommended to use a fourfold rise in IgG titer or an IgM titer of >16 as criteria for acute 
infection [21]. An IgG titer > 16 could indicate past exposure to C. pneumoniae, but no 
criteria for chronic or persistent infection could be formulated [21]. In addition, it has been 
suggested that a single high IgG titer has a poor predictive value [12]. In a study of healthy 
adults without symptoms or signs of infection, 17% fulfilled the criteria of C. pneumoniae 
acute infection (IgG > 512 and/or IgM> 16), while culture and PCR of respiratory specimens 
were negative [33].  
In chapters 3 and 6, we found that C. pneumoniae serology does not correlate with the 
detection of C. pneumoniae by PCR and IHC. This finding confirms the poor agreement 
reported by the majority of the reports addressing this issue [29]. C. pneumoniae has been 
detected by PCR and IHC in seronegative patients, which might implicate false positive PCR 
and IHC or false negative serology, or may be due to the natural delay in immune response, or 
even to lack of immune response. On the other hand, C. pneumoniae culture-positive infection 
episodes without seroconversion have been reported, especially in children [29]. 
In addition to serology, studies have been designed to find evidence that C. pneumoniae is 
present in vascular lesions. The first study that investigated the presence of C. pneumoniae in 
atheromas came from South Africa [81]. The investigators found, by electron microscopy, C. 
pneumoniae-like microorganisms in the core of 7 atherosclerotic plaques. Five of these 
plaques were positive with Chlamydia genus-specific and C. pneumoniae-specific monoclonal 
antibodies in the immunohistochemical staining. Subsequently, a large number of studies on 
the detection of C. pneumoniae were performed using PCR and IHC. These studies reported 
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variable detection rate of C. pneumoniae in atheromas and normal vascular specimens [11, 
12]. 
In the study presented in chapter 2, it was shown that the QIAamp DNA mini kit (Qiagen) is 
a useful and sensitive DNA extraction method for C. pneumoniae detection in vascular tissue. 
Compared with three other DNA extraction methods: NucliSens Kit (Organon), buffer-
saturated phenol (Life Technologies), and Geneclean II Kit (Qbiogene), the purification of C. 
pneumoniae DNA with the QIAamp DNA mini kit was found to be the most sensitive. This 
purification was rapid and easy to perform. However, these findings should be interpreted 
with caution, since we were unable to create exactly reproducible dilution series of C. 
pneumoniae DNA. Moreover, it is not known whether the performance of the four procedures 
in the extraction of C. pneumoniae DNA from spiked materials is the same as their 
performance when used on patient materials. The QIAamp DNA mini kit and two other 
established DNA extraction methods: the High pure PCR template preparation kit 
(Boehringer) and the conventional phenol-chloroform protocol were compared in a multi-
center study [4, 5]. Identical sets of dilution series of atheroma samples spiked with C. 
pneumoniae DNA, atheroma samples spiked with C. pneumoniae, and unspiked samples were 
tested in four laboratories. The results of that study suggested that the QIAamp DNA mini kit 
and the High pure PCR template preparation kit are equally sensitive, and superior to the 
conventional phenol-chloroform protocol. Mygind et al. [64] compared 5 DNA extraction 
methods using different types of samples. They used a real-time PCR for C. pneumoniae 
detection. The DNeasy Tissue kit (uses the same principle as the QIAamp DNA mini kit and 
both are manufactured by Qiagen) was the most sensitive of the five extraction methods when 
used for both pure DNA samples and aorta homogenates spiked with DNA, whereas the 
MagNA Pure method (Roche) was the most sensitive for purified elementary bodies and 
homogenates spiked with elementary bodies.  
We reviewed the results of 22 studies on C. pneumoniae detection by PCR with regard to 
DNA extraction methods used. The QIAamp DNA mini kit was used in 7 studies [42, 43, 49, 
57, 70, 76, 77], and variations of the conventional phenol-chloroform protocol were used in 
15 studies [9, 20, 23, 36, 37, 53-56, 69, 72, 78, 82, 86, 90]. Studies in which the phenol-
chloroform protocol was used to extract DNA obtained significantly more C. pneumoniae 
PCR-positive results than studies that have used the QIAamp DNA mini kit, 32.1% 
(399/1240) and 15.9% (47/295), respectively (p< 0.05). However, this does not necessarily 
imply that the phenol-chloroform is more sensitive than the QIAamp DNA mini kit, since 
there are many variables between the reviewed studies. 
To further assess the link between C. pneumoniae and vascular diseases, we performed PCR 
and IHC staining to examine the presence of C. pneumoniae in clinical specimens. Peripheral 
blood cells (chapters 3 and 5) and vascular tissue (chapters 6, 8 and 9) obtained from patients 
with vascular diseases were tested.  
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The studies described in chapters 3 and 6 were initiated in 1998. In chapter 3, using a 16S 
based single-step PCR, C. pneumoniae DNA was detected in peripheral blood cells of 18 
(20%) of 88 patients with AAA and 8 (9%) of 88 control subjects. The odds ratio for 
association was 2.9 (95% CI, 1.0-8.5), indicating an association between AAA and C. 
pneumoniae. The pathogenesis of AAA is not fully understood, but there is evidence that 
genetic factors are implicated in the development of AAA, which is supported by the familial 
clustering of AAA. Also, several proteolytic factors are considered as risk factors for AAA 
[41, 58]. Interaction between these risk factors probably promotes proteolytic activity in the 
arterial wall, which gives a rise to aneurysm dilatation. We hypothesized that C. pneumoniae 
might induce a chronic immunologic activation causing chronic endothelial cell damage and 
mediating a proteolytic process in the wall of the abdominal aorta [42]. Two previous studies 
on the association between AAA and C. pneumoniae had included control tissues. These 
reports provided conflicting results, Ong et al. [69] found no association, but Petersen et al. 
[76] showed a strong association.  
We also report positive results in chapter 6. Using 16S based PCR, we detected C. 
pneumoniae DNA in 22% (10/45) of atheroma specimens and in 10% (5/50) of aortic 
specimens obtained from patients with cardiovascular disease. Since atheromas were 
significantly more frequently positive in PCR, we suggested that C. pneumoniae is associated 
with vascular disease and that C. pneumoniae might be involved in the development of 
atherosclerosis. 
It has been suggested that in the context of the possible link between C. pneumoniae and 
vascular disease, also the association between vascular disease and other bacteria’s such as 
Mycoplasma pneumoniae should be investigated [85]. This because the similarity in 
epidemiological behavior between M. pneumoniae and C. pneumoniae [85]. In chapter 7, we 
investigated the presence of M. pneumoniae in vascular specimens. Our results showed that 
M. pneumoniae is not associated with vascular disease. We tested atheromas and degenerative 
heart valve specimens by M. pneumoniae PCR. One (2.5%) of the 39 atheromas and two (3%) 
of the 64 degenerative heart valve specimens were PCR positive. These findings were 
confirmed in chapter 6, in that study M. pneumoniae was detected by PCR in one of 95 
vascular specimens. The M. pneumoniae PCR assay used in these two studies (chapter 6 and 
7) has been validated on respiratory samples and it had high sensitivity [34]. However, in the 
absence of the “gold standard” in the diagnosis of M. pneumoniae, the validation of in house 
made M. pneumoniae PCR remains difficult [51]. Quality control studies of M. pneumoniae 
PCRs have revealed both false-negative and false-positive results, indicating deficiency of 
these unstandardized methods [51]. 
Our later studies (chapter 5, 8 and 9) investigating the presence of C. pneumoniae in 
peripheral blood cells and vascular tissue were performed in 2000. In chapter 5, we performed 
PCR to detect C. pneumoniae DNA in peripheral blood cells of patients with venous 
thrombosis and control subjects. The detection rate of C. pneumoniae was very low in the 
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patients and the control subjects 0.5% (1/185) and 0.9% (2/220), respectively. These results 
confirmed the serologic findings that C. pneumoniae is not associated with venous 
thrombosis. The inconsistency in the detection rate of C. pneumoniae by PCR, between this 
study and our early study on AAA (chapter 3) is difficult to explain. In both studies the same 
PCR assay was performed on the same type of specimens (peripheral blood cells), but the 
detection rate varied substantially, 9% in the control subjects of the AAA study and 0.9% in 
the control subjects of the venous thrombosis study. We hypothesized that population 
differences between the two studies, such as the younger age of the subjects in the venous 
thrombosis study, and a poor reproducibility of the PCR assay might be responsible for the 
inconsistency in the detection rate.  
Other investigators have also addressed the issue of inconsistency in the detection of C. 
pneumoniae by PCR. The rate of positive PCR varied among studies from 0% to 100% [11, 
12]. Several possible explanations for this discrepancy have been suggested, such as 
population variations and insufficient blinding procedure [29]. However, there is 
accumulating evidence that variation in methods is the most plausible explanation [12]. C. 
pneumoniae PCR assays are not standardized and none of the available assays has been 
extensively evaluated compared to culture. Moreover, there is no “gold standard” assay that 
allows adequate interpretation of the obtained results [29]. 
Apfalter et al. [4, 5] addressed, in two multicenter studies, the interlaboratory inconsistency 
in the detection of C. pneumoniae DNA. In the first study [4], the agreement between 9 
laboratories in the detection of C. pneumoniae was low, and the rate of positivity ranged from 
0% to 100%. There was no consistency in pattern of positivity and the sensitivity of the assays 
used did not correlate with their detection rate. In addition, the negative control was reported 
positive in 19% of the assays. In the second study [5], the rate of positivity was higher among 
the negative controls than the vascular specimens. No single initially positive result could be 
confirmed after reamplification by a second PCR followed by hybridization with a C. 
pneumoniae-specific probe. They concluded that the reported variability in the detection of C. 
pneumoniae was caused by methodological factors rather than by differences in the 
prevalence of C. pneumoniae in the specimens [5]. It has also been shown that nested PCR 
assays yield more positive results than single-step assays [40]. We reviewed the results 
obtained by nested PCR or single-step PCR in 36 studies on the detection of C. pneumoniae in 
vascular specimens. In 23 studies, 1775 atheroma specimens were tested by a nested PCR 
assay and 497 (28%) specimens were positive [7-9, 16, 24, 49, 53-56, 65-67, 69, 70, 72, 76-
78, 82, 85, 86, 90]. The 13 studies that performed a single-step PCR assay tested 460 
atheroma specimens and detected C. pneumoniae DNA in 89 (19.3%) specimens [3, 13, 20, 
23, 26, 36, 37, 42, 43, 47, 48, 57, 88]. The corresponding percentages for control tissue 
specimens were 10.7% (27/251) for the nested PCR and 3.5% (10/286) for the single-step 
PCR. Although, nested PCR assays produce more positive results, it has been shown that 
these assays have many limitations [5]. Nested PCR assays are prone to contamination and do 
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not allow the use of decontamination treatment with UNG [5]. Therefore, the reliability of the 
results of studies that performed a nested PCR assay has been questioned [5]. 
In chapter 8, we identified methodological factors that might contribute to intra- and 
interlaboratory inconsistency in the detection of C. pneumoniae DNA by PCR. We 
investigated the presence of C. pneumoniae in vascular specimens (61 atheromas and 5 AAA) 
by the PCR assay used in our previous studies (chapter 3, 5 and 6) and by a nested PCR. Also, 
we performed a 16S PCR-based reverse line blot assay to detect C. pneumoniae DNA as well 
as Chlamydia species DNA. All 66 vascular tissue specimens were C. pneumoniae-negative in 
the three PCR assays. In the single-step PCR, if agarose gel electrophoresis was the final 
method of PCR product detection in combination with the use of conventional Taq DNA 
polymerase, 54.5% (36/66) of the samples would have been accepted as C. pneumoniae-
positive. All these samples, however, were negative after hybridization of the PCR products 
with a C. pneumoniae-specific probe. The PCR assay revealed negative results also when 
Amplitaq Gold DNA polymerase was used. The impact of the DNA polymerase might be 
explained by the fact that Amplitaq Gold DNA polymerase leads to the production of more 
specific products than the conventional Taq DNA polymerase. DNA polymerase enzymes like 
Amplitaq Gold or Hotstart that need to be activated at elevated temperature are known to 
enhance the specificity of PCR [44]. The use of Amplitaq Gold DNA polymerase in PCR 
assays has been seldom explicitly reported in studies on the detection of C. pneumoniae. Our 
results stressed the necessity of hybridization with a specific probe as an important measure to 
minimize false-positive PCR signals. Reviewing the results of 2137 specimens tested by PCR 
(chapter 8), we showed that the detection rate of C. pneumoniae in the literature is biased by 
the definition of a positive PCR. In studies that accepted gel electrophoresis signals as PCR-
positive, the detection rate is significantly higher than in those that accepted hybridization 
signals as PCR-positive, 31.6% (204/645) and 24.5% (367/1492), respectively (p< 0.05). It is 
possible that the results of studies without hybridization are confounded by non-specific PCR-
positive signals that are, incorrectly, interpreted as positive.  
In the nested PCR (chapter 8), all specimens were negative both by gel electrophoresis and 
by hybridization. Since the nested PCR was based on the sequence of the OmpA gene, a gene 
that usually shows more sequence variation compared to the 16S rRNA gene, no effect of the 
DNA polymerase was found in this assay. Using the reverse line blot PCR (chapter 8), we 
detected Chlamydia species DNA in 30% (20/66) of the specimens. Sequence analysis of 6 
PCR-positive samples demonstrated the presence of Chlamydia-like microorganisms, 
including Endosymbiont acanthamoebae, Neochlamydia hartmanellae, Chlamydia Research 
Group 52, and Chlamydia Research Group 1. We hypothesized that Chlamydia-like 
microorganisms might influence the results of C. pneumoniae-PCR assays, and they might 
contribute to the inconsistency in the detection of C. pneumoniae. We demonstrated the 
presence of Chlamydia species DNA by reverse line blot PCR in non-clinical samples, 
including elution buffer and distilled water, after passage of the Qiagen columns. This 
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suggests that it is possible that Chlamydia-like microorganisms were not originally present in 
the patients’ specimens, but they might be introduced by contamination [60, 71]. Chlamydia-
like microorganisms may infect free-living amoebae that are common inhabitants of the 
aquatic environment. Amoebae may present a reservoir for these microorganisms, implying 
that Chlamydia-like microorganisms have potential for widespread dissemination [27]. 
Moreover, the 16S rRNA sequence of Chlamydia-like strains has been shown to be highly 
homologous with C. pneumoniae 16S rRNA [27]. The negative results in this study (chapter 
8) stress the inconsistency in the detection of C. pneumoniae at our laboratory, since in our 
initial study (chapter 6) C. pneumoniae DNA was detected by PCR in 22% of atheromas and 
in 10% of aortic specimens. It is noteworthy that our early studies on the detection of C. 
pneumoniae (chapter 3 and 6) provided positive results, whereas our subsequent studies 
(chapter 5 and 8) were negative. Although, the same PCR was used and all tests were 
performed at the same laboratory, there was a major variation in the detection rate between 
the early and the later studies. The results presented in chapter 8 suggest that DNA extraction, 
the type of DNA polymerase, anti-contamination with dUTP/UNG, and hybridization with 
specific probes influence the PCR results. Methodological factors are probably responsible for 
the inconsistency between the results of C. pneumoniae PCR assays. This indicates that the 
results generated by PCR assays, including our own results, are probably biased by a poor 
methodology. 
It has been questioned whether the problem of C. pneumoniae PCR contamination can be 
controlled [5]. Therefore, more efforts have been recently focussed on the establishment of 
quantitative real-time PCR technology [6].  
In chapter 9, we used two recently introduced techniques: a real-time PCR and an industry-
developed research-use-only PCR assay. The real-time PCR requires less manipulation, 
resulting in lower risk of contamination; it is an automated and closed system; and it combines 
amplification, hybridization and quantitative product detection [6]. The industry-developed 
PCR research assay ensures consistent performance. Although the real-time PCR and the 
industry-developed PCR are not standardized, the first reports on the evaluation of these tests 
suggest that they are sensitive, specific and reproducible [6, 15].  
The clinical trial described in chapter 9 was designed to examine whether clarithromycin 
treatment can eradicate C. pneumoniae from vascular tissue of patients with coronary artery 
disease (CAD). Patients with CAD, waiting for coronary artery bypass graft surgery were 
enrolled and randomly assigned to receive clarithromycin 500 mg or placebo once daily, from 
the day of inclusion till surgery. During surgery, vascular specimens were obtained and 
subsequently tested by a real-time PCR and an industry-developed PCR. These two PCR 
assays failed to detect C. pneumoniae DNA in any specimen. The negative results of the PCR 
assays indicate that there is no evidence for acute C. pneumoniae infection in vascular tissue 
of CAD patients. Other possible explanations for the negative results of the PCR assays could 
be the low DNA concentration in the test samples and the patchy distribution of C. 
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pneumoniae DNA in vascular tissue [16]. We were not able to demonstrate the effect of 
clarithromycin on the presence of C. pneumoniae DNA in vascular tissue, since all specimens 
were negative in the PCR assays. Melissano et al. [62] evaluated the effect of roxithromycin 
on C. pneumoniae in carotid atheromas. They found that roxithromycin treatment was 
effective in eradicating C. pneumoniae from carotid atheromas. An important difference 
between our study and the study of Melissano et al. is the high detection rate of C. 
pneumoniae DNA in their study. However, they used one unstandardized conventional semi-
nested PCR assay to detect C. pneumoniae DNA. Taking the limitations of the design of the 
study of Melissano et al. (open and not placebo-controlled) into account, the reliability of their 
results might be questioned. 
We used, as described in chapter 6 and 9, IHC staining to detect C. pneumoniae antigens in 
vascular specimens obtained from CAD patients. In chapter 6, we reported positive IHC 
staining for C. pneumoniae-MOMP in 60% (25/42) of the atheromas and in 9% (4/46) of the 
aortic specimens. In chapter 9, we used IHC to assess the effect of clarithromycin treatment 
on the presence of C. pneumoniae in vascular tissue of CAD patients. IHC detected C. 
pneumoniae-MOMP antigen in 73.8% of specimens in the clarithromycin group and 77.0% of 
specimens in the placebo group (p = ns). Chlamydia-LPS antigen was detected by IHC in one 
specimen from the placebo group. High detection rate of C. pneumoniae antigens by IHC has 
been reported by others [12]. However, protocols of performance and interpretation of IHC 
are not standardized [21]. IHC requires a subjective reading and its interpretation remains 
difficult because of background staining and nonspecific staining with antigenic components, 
such as inflammatory cells and tissue components, in vascular specimens [69, 82, 85]. It is 
also possible that components of Chlamydia-like microorganisms can cause cross-reactivity to 
the monoclonal antibodies used in IHC staining [60]. 
In chapter 6, we reported a statistically significant correlation between PCR and IHC in the 
detection of C. pneumoniae in atheromas. Unfortunately, we did not use established 
guidelines for the interpretation of agreement between tests [1]. According to these guidelines, 
the agreement between PCR and IHC found in our study (chapter 6) and most studies 
reviewed in chapter 6 is weak to fair. A good agreement is valid only for two of the reviewed 
studies [42, 82]. 
In the studies described in chapters 6 and 9, PCR and IHC produced conflicting results. 
Inconsistency between the results of PCR and IHC and the abundance of MOMP antigen and 
low detection rate of LPS antigen, in absence of C. pneumoniae DNA in vascular specimens 
has been reported before [60, 61]. This inconsistency might be partly explained by the biology 
of chlamydiae [31, 35]. Alternation of activity and latency characterizes infections with 
chlamydiae. In advanced chlamydiae infections, the pathogen is no longer present, whereas its 
antigens can persist for a long time. The persisting antigens may cause a cascade of events 
leading to fibrosis and scarring [31, 35]. 
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The results of our clinical trial (chapter 9) indicated that clarithromycin treatment of CAD 
patients had no effect neither on the presence of C. pneumoniae in vascular tissue nor on 
circulating Chlamydia IgG titers. We concluded that antibiotic treatment of CAD patients is 
not indicated and it may not be beneficial, since C. pneumoniae infection in these patients is 
probably not acute and viable pathogens are no longer present in their vascular tissue.  
A major finding in this study was, that in vascular tissues of patients with advanced CAD, 
no C. pneumoniae DNA could be detected, but only antigen debris of C. pneumoniae. In the 
light of these findings, it can be questioned whether an effect of antibiotics in patients with 
advanced atherosclerosis could be expected. This may explain the results of many clinical 
trials that failed to demonstrate any beneficial effect of antibiotic treatment in patients with 
vascular disease [2, 28, 38, 50, 68, 84, 89]. 
In conclusion, the results of this thesis do not support the hypothesis of a causal relationship 
between C. pneumoniae and vascular diseases. Antibiotic treatment has no effect on the 
presence of C. pneumoniae in vascular tissue of patients with advanced CAD. The available 
diagnostic methods of C. pneumoniae infection lack sufficient reliability and standardization. 
The results of C. pneumoniae PCR assays are inconsistent. The agreement between the results 
of C. pneumoniae serologic assays is poor. These limitations have important implications on 
the assessment of the possible role of C. pneumoniae in the pathogenesis of vascular diseases. 
The perceived association between C. pneumoniae and vascular diseases is influenced and 
probably biased by methodological factors. Further efforts should focus on optimizing and 
standardizing diagnostic methods of C. pneumoniae infection. 
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Chlamydia pneumoniae behoort, volgens de nieuwe classificatie van de familie 
Chlamydiaceae, tot het genus Chlamydophila. Binnen het genus Chlamydophila worden 6 
species onderscheiden: pneumoniae, psittaci, pecorum, abortus, felis en caviae. Het genus 
Chlamydia heeft 3 species: trachomatis, suis en muridarum. Volgens de “oude” classificatie 
had de familie Chlamydiaceae één genus: het genus Chlamydia. In dit proefschrift, hanteren 
wij de oude benaming Chlamydia pneumoniae omdat deze beter bekend is onder de 
microbiologen en de klinici. Chlamydiae zijn op te vatten als Gram-negatieve bacteriën, die 
als gevolg van hiaten in hun metabolisme niet in staat zijn tot zelfstandig extracellulair 
bestaan en daardoor gedwongen zijn tot intracellulair parasitisme. Chlamydiae zijn gevoelig 
voor bepaalde antibiotica, o.a. voor macroliden en tetracyclines.. C. pneumoniae veroorzaakt 
pneumonie, bronchitis, pharingitis en sinusitis. De meeste kinderen raken op jonge leeftijd 
geïnfecteerd met C. pneumoniae. Op volwassen leeftijd (>50 jaar) zijn bij 60-80% van de 
mensen antistoffen tegen C. pneumoniae aantoonbaar. 
Verschillende risicofactoren zijn betrokken bij het ontstaan van atherosclerose, het 
belangrijkste proces in coronair vaatlijden. Hypercholesterolemie, hypertensie, diabetes 
mellitus en roken zijn geïdentificeerd als factoren die een rol spelen in de pathogenese van 
atherosclerose. Echter, deze risicofactoren kunnen het voorkomen van coronair vaatlijden 
alleen bij 50-70% van patiënten verklaren.  
Aneurysma van de aorta abdominalis (AAA) is een gelokaliseerde chronische dilatatie in de 
aorta, die ontstaat als gevolg van afbraak van extracellulaire matrixeiwitten en vervolgens van 
elastine- en collageenvezels in de aortawand. Genetische en familiare factoren zijn betrokken 
bij het ontstaan van AAA, echter de pathogenese van AAA is niet helemaal opgehelderd. 
Veneuze trombose wordt gekenmerkt door trombosevorming als gevolg van 
endotheelcelbeschadiging, stase en verhoogde stollingsactiviteit. Verworven en genetische 
factoren spelen een rol bij het ontstaan van veneuze trombose. Echter, bij eenderde van de 
patiënten blijft de pathogenese van veneuze trombose onverklaarbaar. 
Potentiële risicofactoren voor vaatziekten, zoals een mogelijke rol van chronische infecties, 
kregen in de afgelopen decennia veel aandacht. Finse onderzoekers vonden eind tachtiger 
jaren een associatie tussen een hoge antistoffentiter tegen C. pneumoniae en coronair 
vaatlijden. Sindsdien is er wereldwijd veel onderzoek gedaan naar een mogelijke rol van C. 
pneumoniae bij vaatziekten, zoals coronair vaatlijden, AAA en veneuze trombose. In de 
studies die beschreven zijn in dit proefschrift wordt de associatie tussen C. pneumoniae en 
vaatziekten onderzocht.  
In hoofdstuk 2 worden vier verschillende procedures voor de extractie van C. pneumoniae 
DNA uit vaatwandmonsters vergeleken. De onderzochte procedures zijn: NucliSens, QIAamp 
DNA MiniKit, buffer-saturated phenol, en Geneclean II. In dit onderzoek hebben wij 30 
bioptiemonsters van de aorta gebruikt. De resultaten lieten zien dat de QIAamp DNA MiniKit 
een gemakkelijk uit te voeren procedure is, met de hoogste gevoeligheid van detectie.  
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Hoofdstukken 3 en 4 beschrijven een patiënt-controle onderzoek naar de relatie tussen C. 
pneumoniae en AAA. In dit onderzoek werden perifere bloedcellen en serummonsters van 88 
patiënten met AAA en 88 gezonde personen onderzocht. Met polymerase kettingreactie 
(PCR) werd C. pneumoniae DNA vaker gedetecteerd in perifere bloedcellen van patiënten 
met AAA dan bij gezonde personen. De serologische resultaten waren inconsistent. Omdat de 
serologische “gouden standaard” test voor  C. pneumoniae ontbreekt, hebben wij de 
antistoffen tegen C. pneumoniae bij patiënten en controles met 5 verschillende serologische 
testen bepaald. Slechts in een van de 5 testen (MRL-MIF), werden antistoffen tegen C. 
pneumoniae vaker aangetroffen bij de patiënten dan bij de gezonde personen. Deze bevinding 
kon echter bij een hoog afkappunt van de MRL-MIF (IgG>512) niet bevestigd worden. In de 
andere 4 serologische testen werd geen significant verschil tussen AAA patiënten en controles 
gevonden. Bovendien was de overeenstemming tussen de resultaten van de 5 testen in het 
algemeen zwak. Op basis van de PCR resultaten werd geconcludeerd dat C. pneumoniae 
geassocieerd kan zijn met AAA. Deze associatie werd niet ondersteund door de serologische 
resultaten, en was afhankelijk van welke serologische test werd gebruikt. Geconcludeerd werd 
dat de beschikbare, niet gestandaardiseerde serologische testen, de resultaten met betrekking 
tot de associatie tussen C. pneumoniae and AAA beïnvloeden. Deze bevinding verzwakt de 
hypothese die veronderstelt dat C. pneumoniae een rol kan spelen in de pathogenese van 
AAA. 
In hoofdstuk 5 wordt ingegaan op de vraag of C. pneumoniae een rol kan spelen bij het 
ontstaan van veneuze trombose. Ook wordt de betrokkenheid van C. pneumoniae bij de 
inflammatie (IL-6 en IL-8) die geassocieerd is met veneuze trombose bestudeerd. Er werd een 
patiënt-controle onderzoek uitgevoerd, waarbij de patiënten recidiverende veneuze trombose 
hadden. Voor dit onderzoek waren perifere bloedcellen en serummonsters van patiënten (n = 
185) en controles (n = 220) beschikbaar. Zowel een serologisch als een moleculair verband 
tussen veneuze trombose en C. pneumoniae kon niet worden aangetoond. De aanwezigheid 
van C. pneumoniae antistoffen was niet geassocieerd met een verhoogd risico van veneuze 
trombose. C. pneumoniae DNA werd gedetecteerd bij één patiënt en twee gezonde controles. 
De concentraties van IL-6 en IL-8 bij patiënten en controles waren niet geassocieerd met C. 
pneumoniae antistoffentiter. Wij concludeerden dat C. pneumoniae waarschijnlijk geen rol 
speelt bij het ontstaan van veneuze trombose, en dat C. pneumoniae niet verantwoordelijk is 
voor de ontstekingsreactie die geassocieerd is met veneuze trombose. 
In hoofdstuk 6, 8 en 9 werd de relatie tussen C. pneumoniae en atherosclerose bestudeerd. In 
hoofdstuk 6 beschrijven wij een onderzoek waarbij atherosclerotische coronaire 
vaatwandmonsters en macroscopisch gezonde aortawandmonsters werden afgenomen tijdens 
vaatchirurgie bij patiënten met ernstig coronair vaatlijden. De aanwezigheid van C. 
pneumoniae DNA of C. pneumoniae membraaneiwit (MOMP) werd in deze monsters met 2 
methoden onderzocht, PCR en immunohistochemie (IHC), respectievelijk. Ook werden de 
antistoffen tegen C. pneumoniae in serummonsters van deze patiënten bepaald. C. 
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pneumoniae DNA en MOMP werden in de atherosclerotische vaatwandmonsters vaker 
gedetecteerd dan in de aortawandmonsters. Deze resultaten suggereren dat er een verband 
bestaat tussen C. pneumoniae en atherosclerose. De overeenstemming tussen de serologische 
resultaten en respectievelijk de PCR en IHC resultaten was zwak. Een zwakke tot matige 
overeenstemming was ook gevonden tussen de resultaten van PCR en IHC. 
In hoofdstuk 7 gaan we in op de hypothese die veronderstelt dat Mycoplasma pneumoniae 
een plausibele kandidaat kan zijn om een rol in de pathogenese van atherosclerose te spelen. 
Om dit te onderzoeken hebben wij 39 atherosclerotische coronaire vaatwandmonsters en 64 
degeneratieve hartklepmonsters, van patiënten die operatief zijn behandeld, onderzocht met 
M. pneumoniae PCR. M. pneumoniae DNA werd gedetecteerd in één atherosclerotisch 
vaatwandmonster en in 2 degeneratieve hartklepmonsters. Daarom kan geconcludeerd worden 
dat M. pneumoniae is niet geassocieerd met atherosclerose en zeer waarschijnlijk geen rol 
speelt in de pathogenese van deze ziekte. 
In hoofdstuk 8 wordt de invloed van methodologische factoren in PCR op de detectie van C. 
pneumoniae DNA in vaatwandmonsters beschreven. Vaatwandmonsters (61 atheromas en 5 
AAA) werden afgenomen bij 66 patiënten met vaatlijden en werden getest met 3 verschillende 
PCR methoden, een ‘reverse line blot’ PCR, een ‘single-step’ PCR, en een ‘nested’ PCR. De 
laatste 2 PCR testen werden met twee verschillende DNA polymerase enzymen uitgevoerd. 
Dit onderzoek heeft aangetoond dat de methodologie een belangrijke invloed op de detectie 
van C. pneumoniae DNA heeft. Het type DNA polymerase, anticontaminatie met dUTP/UNG, 
hybridisatie met een specifieke probe, en DNA extractie met columns werden geïdentificeerd 
als methodologische factoren die de resultaten van de PCR kunnen beïnvloeden. Er werd 
geconcludeerd dat de associatie tussen C. pneumoniae en vaatziekten wordt vertekend door de 
niet-gestandaardiseerde methodologie.  
In hoofdstuk 9 wordt het effect van clarithromycine op de aanwezigheid van C. pneumoniae 
in vaatwandmonsters en op Chlamydia IgG antistoffentiter in serum bij patiënten met coronair 
vaatlijden bestudeerd. Daarvoor hebben wij een placebo-gecontroleerd, dubbel blind, 
gerandomiseerd interventie onderzoek verricht. Patiënten met coronair vaatlijden (n = 76) die 
op de wachtlijst voor ‘coronary artery bypass graft’ operatie stonden, kregen tot de dag van de 
ingreep, eenmaal daags clarithromycine SR 500 mg of placebo. Tijdens de ingreep werden 
vaatwandmonsters afgenomen. Bloedmonsters werden bij inclusie en 8 weken na de ingreep 
afgenomen. De vaatwandmonsters werden met 3 methoden getest: IHC, ‘real-time’ PCR en 
‘industry-developed research-use-only’ PCR. Er was geen significant verschil tussen de twee 
onderzoeksgroepen in de detectie van C. pneumoniae membraaneiwitten. Ondanks het 
gebruik van twee PCR methoden werd C. pneumoniae DNA in geen vaatwandmonster 
gedetecteerd. Clarithromycine had geen effect op de Chlamydia IgG antistoffentiter. Er werd 
geconcludeerd dat er geen aanwijzingen zijn voor levende C. pneumoniae in de vaatwand bij 
patiënten met coronair vaatlijden, en dat de behandeling met clarithromycine bij deze 
patiënten geen effect op C. pneumoniae heeft.  
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Het ontbreken van gestandaardiseerde methoden voor de detectie van C. pneumoniae-DNA, 
-antigenen, en -antistoffen is een complicerende factor in de evaluatie van de rol van C. 
pneumoniae in de pathogenese van vaatziekten. Methodologische factoren beïnvloeden de 
resultaten van seroepidemiologische en detectieonderzoeken, en als gevolg daarvan kan een 
mogelijke associatie tussen C. pneumoniae en vaatziekten vertekend worden. 
De bevindingen van de studies beschreven in dit proefschrift ondersteunen niet de theorie 
van een causale relatie tussen C. pneumoniae en vaatziekten. De associatie tussen deze 
bacterie en vaatziekten is inconsistent. Antimicrobiële behandeling heeft geen invloed op de 
aanwezigheid van C. pneumoniae in de vaatwand bij patiënten met coronair vaatlijden. 
Verdere studies moeten gericht zijn op de optimalisering en standaardisering van C. 
pneumoniae diagnostische methoden. 
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